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The human genome project: the current
status, an overview
NK Spurr
SmithKline Beecham Genetic Technologies Department, Biopharmaceutical
R and D, NFSP(N), Harlow, Essex, CM19 5AW, UK
The ultimate aim of the Human Genome Project is to obtain the
complete nucleotide sequence of each chromosome. This requires
the construction of several types of maps of varying density,
leading to the latest generation of maps suitable for sequencing.
The construction of these maps has generated many valuable
resources that can be used in the identification of new genes, for
example radiation hybrids, YAC, BAC and PAC libraries. One of
the most important resources has been that generated by shotgun
sequencing ofcDNAs to generate expressed sequence tags (ESTs).
These have been used to identify new genes, and many have been
localized on human chromosomes, leading to an increase in the
identification of disease-causing mutations through a candidate
gene approach.
The Human Genome Project is now moving into its final phase,
with the construction of detailed physical maps as a prelude to
DNA sequencing. Several chromosomes are now being sequenced
and over the next few years significant progress in this area will be
made. Early in the next century, the complete nucleotide sequence
will be available. This has led to a realignment by many laborato-
ries looking towards the post-genome phase ofthe project towards
an understanding of gene function and the complex interactions
between genes.
This talk will present an overview ofthe project and will discuss
some of the future developments, particularly in the context of
a greater understanding of disease and the development of new
therapies.
Advances in the development of gene
targeting agents
D Thurston
CRC Gene Targeted Drug Design Research Group, School of Pharmacy and
Biomedical Sciences, University of Portsmouth, UK
As the Human Genome Project progresses, there is growing
interest in agents that can recognize and interact with specific
sequences of DNA. Such agents have potential as gene regulators
with possible therapeutic application in the treatment of genetic
disorders, including some cancers, as selective anti-infective
agents and as probes and tools for use in molecular biology.
There are two broad approaches to gene targeting: the 'antigene'
and 'antisense' strategies. The objective ofthe antigene strategy is
to develop agents that target DNA itself, potentially down-regu-
lating specific genes. The alternative antisense strategy involves
agents that target the corresponding messenger RNA, thus
preventing production of an aberrant protein. Two main types of
agent are under development. First, the macromolecular approach
involves the development of nucleic acid or protein-based agents
to target DNA or mRNA sequences. The second approach
involves small molecules based on known natural and synthetic
products. The latter have the disadvantage of a more limited
sequence selectivity (at present) but the advantage of behaving
more like commonly used therapeutic agents in terms of stability,
cell permeability, biodistribution and cost. The Portsmouth CRC
Group has carried out extensive studies on the pyrrolobenzodi-
azepine (PBD) class of DNA interactive agent. Using a combina-
tion of modern drug design technologies, considerable progress
has been made in extending the limited 3-bp sequence selectivity
ofthe PBDs to 7 bp, and molecules with longer sequence recogni-
tion are in the pipeline. Furthermore, it has now been demon-
strated that the PBDs penetrate cell membranes and bind
sequence-selectively to the intended target sequences in the
nucleus of cells. This presentation will include an overview of
progress in the general area ofgene targeting and a specific update
on progress with the pyrrolobenzodiazepine group of agents.
Application of 'one-bead one-compound'
combinatorial library method for cancer
research and drug discovery
KS Lam
Arizona Cancer Center, Department of Medicine, Microbiology and
Immunology, University of Arizona, Tucson, AZ 85724, USA
Combinatorial chemistry has been a rapidly developing field in
the last 7-8 years. In addition to facilitating the drug discovery
process, combinatorial chemistry is also extremely useful as a tool
for basic research. Virtually every major pharmaceutical company
has now developed a combinatorial chemistry programme in-
house, or have acquired the technology for their drug discovery
efforts. Combinatorial chemistry involves three discrete steps: (1)
to generate a library of compounds by randomly joining various
pieces of the molecule together, (2) to screen the library for a
specific biological, chemical or physical property and (3) to deter-
mine the chemical structure ofthe active compound.
In the 'one-bead one-compound' combinatorial library method
(Lam et al, 1991, Nature 354: 82-84), the compounds are chemically
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synthesized on beads (e.g.
- 100 mm diameter) using a 'split
synthesis' approach. This results in a library of compound beads on
which each bead expresses only one chemical entity, although there
are approximately 1013 copies of the same compound on one bead.
The compound bead library can then be screened for a specific
biological property, and the positive bead isolated for structure deter-
mination. Various applications of this combinatorial library method
for basic cancer research and cancer drug discovery will be
discussed. These include the identification ofpeptides for lymphoma
cell surface targeting, elucidation of substrate motifs for protein
tyrosine kinases and discovery of anti-cancer agents.
Local and systemic strategies for gene
replacement for cancer
JA Roth, SG Swisher, DD Lawrence, BL Kemp,
CH Carrasco, AK El-Naggar, FV Fossela, BS Glisson,
WK Hong, FR Khuri, JM Kurie, JC Nesbitt, K Pisters,
JB Putnam, DS Schrump, DM Shin and GL Walsh
Department of Thoracic and Cardiovascular Surgery, UTMD Anderson
Cancer Center, Houston, TX 77030, USA
Advances in our understanding of the molecular genetics of lung
cancer present an opportunity to develop prevention and treatment
strategies based on the reversal of specific genetic lesions. Several
experimental observations have suggested that correction ofgenetic
abnormalities in the tumour cell could result in clinically significant
tumour regression, and that corrective genes could be delivered by
viral vectors. Viral gene transfer is more efficient in cancer cells
than expected from studies in normal tissues. Viral vectors spread
readily through tumours following single intratumoral injections.
Transduced cells mediate bystander killing of non-transduced cells.
Thus transduction of all tumour cells is not required as transduced
cells can inhibit the growth of non-transduced cells. Human cancer
cells have multiple genetic abnormalities. Correction of all these is
not practical with current gene delivery systems. However, correc-
tion of critical single genetic lesions can cause regression of human
tumours. Regional administration of viral vectors expressing wild-
type tumour-suppressor gene p53 prevents tumour growth for
tumours with p53 mutations in orthotopic tumour models and medi-
ates regression of large established tumours. These studies provided
a rationale for clinical protocols to replace a defectivep53 gene with
intratumour injection of recombinant retrovirus or adenovirus
expressing normal p53. Patients (pts) who have failed conventional
therapy with unresectable lung cancer obstructing a bronchus,
extensive local regional tumour or isolated metastases that have a
p53 mutation undergo direct intratumour injections with the retro-
viral supernatant. Nine pts have been entered on this protocol. The
presence of vector-derived p53 DNA has been shown in post-treat-
ment biopsies by polymerase chain reaction (PCR). In situ
hybridization studies show nuclear localization of the vector. Post-
treatment biopsies show increased apoptosis by TUNEL staining.
Three pts have shown tumour regression. To date, no grade LI or
higher vector-related toxicity has been observed. We evaluated the
safety and gene transfer efficacy of monthly intratumoral injections
of a recombinant adenovirus containing wild-type p53 (Adp53) in
23 pts with advanced NSCLC who failed conventional treatments.
Adp53 doses were escalated from 106 plaque-forming units (pfu) in
log increments to 10" pfu. Pts were treated with or without cisplatin
(CDDP) 80 mg m-2 i.v. over 2 h given 3 days before Adp53 injec-
tion. Adp53 vector was injected monthly into the same primary or
metastatic tumour under computerized tomography (CT) guidance.
No significant vector-relatedtoxicity was seen with up to6-monthly
injections. The severity of CDDP-associated toxicity (grade II or
higher) was not increased with co-administration ofAdp53. Clinical
responses were evaluated with monthly abdominal and chest CT
scans. Clinical responses with >50% regression of the injected
tumour were observed and have been durable from 4 to I1+ months.
To date, fourmajor responses have been observed in thelung cancer
trial. In addition, of the first 35 patients on whomcomplete data are
available, 5 of 14 (36%) receiving 108 Adp53 alone orhigher doses
had growth arrest of their tumour for >4 months,and 6 of 15 (40%)
patients receiving Adp53 + CDDP hadgrowth arrest oftheir tumour
for . 4 months despite three of the six progressing on CDDP or
carboplatin previously. Post-treatment tumour biopsies demon-
strated vector DNA by PCR, p53 transgene expression by reverse
transcriptase-PCR and immunohistochemistry, increased necrosis
on H and E sections and increased apoptosis by in situ TUNEL
staining. Transgene expression occurred in post-treatment tumour
biopsies in pts with circulating antibodies to adenovirus. There was
no change in the inflammatory cells infiltrating the tumour,
suggesting that non-specific inflammation was not responsible for
the therapeutic effects. These results suggest that adenoviral medi-
ated p53 gene transfer can be successfully accomplished with
minimal toxicity in pts with lung cancer. Adp53 clinical activity
appears improved athigher doses ofvector and when used in combi-
nation with CDDP.
Tumour-selective targeting of prodrug
activation
N Lemoine
ICRF Molecular Oncology Unit, Imperial College School of Medicine,
Hammersmith Campus, London W12 ONN, UK
The principle of genetic prodrug activation therapy (GPAT) is to
take advantage of the transcriptional differences between normal
and tumour cells, or between the cells of one tissue and the rest of
the individual. Expression of a gene that encodes a prodrug-
activating enzyme is directed by a tumour- or tissue-specific gene
promoter so that only these cells should become susceptible to the
toxic effects of the prodrug when it is subsequently administered
systemically. A variety of enzyme/prodrug systems are under
development, all of which have advantages and disadvantages in
particularapplications. Most studies have beenperformed with the
cytosine gene and theherpes simplex virusthymidine kinase gene.
Genes selectively expressed or overexpressed in cancer may be
exploited as targets for therapy. The characterization of their tran-
scriptional regulatory elements is crucial to the design of selec-
tively expressed constructs. A variety of gene promoters might be
exploited for GPAT in breast cancer, and already in our own labo-
ratory encouraging results have been reported with the human
ERBB2 promoter and MUC1 promoter.
Selective delivery may be simply achieved where there is an
actively proliferating population of tumour cells in a quiescent
background (brain tumours for instance) by using retroviruses that
preferentially infect dividing cells. In other situations, selective
delivery can be achieved by targeting cell surface receptors that
mediate internalization. Many growth factor receptors are prefer-
entially overexpressed in cancer, and some of these have been
successfully exploited forligand-mediated gene delivery.
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Cancer vaccines: prospects and
problems
TBlankenstein
Max-Delbruck-Center of Molecular Medicine, Robert-Rossle-Strape 10,
13122 Berlin, Germany
Cytokines provided locally at the tumour site may initiate an effec-
tive antitumour immune response that leads to rejection of a
tumour that would otherwise grow progressively. Experimentally,
this can be tested by gene transfer into cultured tumour cells
followed by the analysis of the tumorigenicity of such genetically
engineered cells. This approach allows analysis of the function of
a given cytokine in vivo and elucidation of the therapeutical value
ofgenetically engineered tumour cells as vaccines. Our experience
includes experiments with about ten cytokines, and the results can
be summarized as follows: (1) some cytokines possess anti-tumour
activity in this system, others do not; (2) a local and continuous
cytokine supply seems to be essential for tumour rejection; (3) the
tumour cell-derived cytokines act in a dose-dependent manner and
in the absence of systemic toxicity; (4) the immunological effector
mechanisms induced by different cytokines are partly cytokine
specific, partly redundant (and usually involve T-cell-dependent
and -independent mechanisms); (5) tumour rejection and mecha-
nism thereof may be different with different tumour cell lines
transfected with the same cytokine gene. Cytokine gene-modified
tumour cells as vaccines are currently being tested in clinical trials.
However, critical parameters, such as vaccine potency of cytokine
gene-transfected tumour cells, optimal level of cytokine expres-
sion, reasons for varying vaccine effects in different tumour
models, influence of irradiation of vaccine cells on their efficacy
and attempts to improve vaccine efficacy (e.g. by coexpression of
cytokines and T-cell co-stimulatory molecules, such as B7) have to
be further addressed in experimental tumour models.
Cancer therapy in 2020
K Sikora
WHO Cancer Programme, Lyon, France, and Department of Cancer
Medicine, Imperial College School of Medicine, Hammersmith Hospital,
London W12 ONN, UK
Over the next 25 years there will be major changes in the patterns
of cancer incidence as the age distribution shifts in the population.
Early detection and the ability to tailor treatments to the genetic
characteristics of the tumour can be expected to improve cure
rates. New diagnostic techniques involving molecular genetics
will almost certainly allow the identification of high-risk groups
for intensive screening and the application of preventive interven-
tions. Early diagnosis will be enhanced by novel imaging tech-
nology, based on computerized three-dimensional reconstruction
together with novel tumour markers.
The main modalities of treatment will improve. Surgery will
result in increased organ preservation relying on minimally invasive
techniques, computer-assisted virtual reality systems and robots.
Eventually, surgery may even be replaced entirely with novel
therapies. Radiotherapy will develop through multimedia imaging
of tumour and normal tissues using computer optimization to
obtain the best physical and biological therapeutic ratios. Designer
fractionation based on individually predicted differential sensitivity
to radiation will be possible through a greater understanding of the
genes involved in DNA repair.
Novel systemic therapies are likely to have the greatest impact
on cancer mortality. A new golden age of drug discovery is likely
with the logical design ofsmall molecules interfering with specific
targets, such as signal transduction, transcription control, mitosis
and apoptosis. The pace of acquisition ofmolecular knowledge on
cancer is rapidly accelerating. The proteins encoded by both onco-
genes and tumour-suppressor genes provide a promising hunting
ground in which to design and test new anti-cancer drugs. Four to
six genetic changes appear necessary to produce most human
cancers. Over the next 5 years a much clearer understanding ofthe
molecular pathogenesis of several specific malignancies is likely.
One of the greatest challenges will be caring for people with
cancer, using the new technology in the face of declining orga-
nized religion and cohesive family structures. An increasing
number of patients will neither die from their cancer nor be cured
of it, but must learn to live with their disease, often being given
complex therapies to control it for many years.
The gene therapy industry - technology
triumphs over common sense
ME Gore
The Royal Marsden Hospital, London SW3 6JJ, UK
All gene therapy strategies have to address three issues: the
method oftumour cell kill, the choice ofvector and the targeting of
product to tumour cells. These three issues are not very different
from those that face workers in the field ofdrug development. The
problems that have to be overcome for successful cancer therapy
are the same whether drugs or genes are used as a therapeutic. The
ability to manipulate DNA sequences and insert them into cells in
vitro with predictable effects has been very successful. Problems
arise when attempts are made to translate these strategies into
patients. The main areas ofgene therapy are gene-directed enzyme
prodrug therapy, corrective therapy and immunotherapy. There is a
requirement in the first two strategies to have at least a very high
proportion of tumour cells infected by the transgene without
necessarily affecting normal cells. Most laboratory gene therapy
programmes have concentrated on ways ofkilling tumour cells but
this is not the major problem in cancer therapy. Tumour cell
targeting is the key to successful cancer treatment, and practical
ways of achieving this via gene therapy techniques are poorly
developed. Many methods involve hybrid delivery systems using
ligand binding technology that is often not exclusive to recombi-
nant DNA technology. The strategy of achieving directed
immunotherapy theoretically gets round the problem of specific
tumour cell targeting, but the history of successful immunotherapy
is not a glorious one. The most promising strategy for gene therapy
involves tumour- and tissue-specific promotion, and it is this area
of research that is most likely to lead to successful gene therapy
approaches.
Drug or gene therapy for ovarian cancer:
which is the best hope for the future?
SB Kaye
CRC Department of Medical Oncology, University of Glasgow, Bearsden,
Glasgow G61 1BD, UK
Ovarian cancer treatment is limited by the development of
drug resistance, whose underlying mechanisms are not yet
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clarified. A key feature is failure of cells to undergo apoptosis
after DNA damage, and this is linked to dysfunctional p53 in
resistant cells. New agents, including taxoids and topoisomerase
I inhibitors, can circumvent this resistance in vitro and do have
clinical use, but they still have the classical problems of
chemotherapy, i.e. a cellular target that is not selective for
cancer cells.
The alternative approach, i.e. using tumour-specific promoters
to provide selective gene therapy, has attracted considerable atten-
tion, but problems ofdelivery remain formidable. A novel form of
'genetic therapy' involves targeting ofresistant tumour cells using
the EIB genome-deleted attenuated human group C adenovirus
Onyx-0 15. This can replicate selectively and then lyse cells with
dysfunctional p53, and both in vitro and in vivo data confirm its
activity in ovarian cancer models, including human tumour
xenografts. Clinical trials using the intraperitoneal route are
ongoing. Meanwhile experimental data indicate that optimal
results may be obtained by a judicious combination of virus and
drug therapy. Therefore, it is conceivable that, rather than choose
between gene or drug therapy, the oncologist of the future will
be fully employed using rational combinations of both forms of
treatment.
Selective cancer therapy with drugs -
we've only just begun
DR Newell
Cancer Research Unit, University of Newcastle, Newcastle NE2 4HH, UK
Cancer is a genetic disease, and hence it is tempting to conclude
that curing cancer will ultimately require gene therapy. However,
cancer results from two types of gene defect, oncogene activation
and tumour-suppressor gene inactivation, and gene therapy may
not be relevant to both problems. Thus, while gene replacement to
overcome tumour-suppressor gene malfunction is an obvious
approach, with the exception of antisense strategies, it is not clear
how gene therapy will correct problems resulting from proto-
oncogene mutation, amplification or overexpression. In contrast,
drug therapy can be used to both inhibit oncogene function and
substitute for the actions of tumour-suppressor genes. For
example, inhibitors ofoncogenic tyrosine kinases are now in clin-
ical trials, and small-molecule cyclin-dependent kinase inhibitors,
to mimic the effects of natural inhibitors produced by p53 activa-
tion, are being developed. In addition to these conceptual attrac-
tions, small-molecule drugs can exploit a wealth of experience in
medicinal chemistry, structural biology, preclinical and clinical
pharmacology. Furthermore, small-molecule drug therapy avoids
the problems ofdelivery inherent in gene-based approaches.
If there were currently no examples of curative therapy with
small-molecule drugs, pessimism about the future of cancer
chemotherapy would be warranted. However, experience with
haematological malignancies, paediatric solid tumours and certain
adult cancers has shown that curative cancer therapy with small
molecules is feasible, albeit at levels and with toxicities that are
not acceptable. Given that, for the first time, drugs targets are
being exploited that are linked to the molecular pathology of
cancer, there is genuine reason for optimism about future
prospects for small-molecule drugs.
Evidence for an immunomodulatory role
for ox-melanocyte-stimulating hormone
(oc-MSH) in cutaneous and ocular
melanocytes
SJ Hedley', M Wagner', DJ Gawkrodger2, AP Weetman',
IG Rennie3 and S MacNeil'
University Departments of 'Medicine, 2Dermatology, and 3Ophthalmology
and Orthoptics, Sheffield S5 7AU, UK
oc-MSH, a defined pigmentary hormone in many species, has a
broad spectrum of biological actions, including the reduction of
experimentally induced fever in animals. We speculated that it
may assist local melanocytes to resist UV-induced damage and
local inflammation. Such an action could prevent melanocytes
becoming a premature target for the immune system. In
melanoma, this mechanism could help metastatic cells escape the
attentions of the immune system.
We investigated the effects of ox-MSH on TNF-oc stimulated
ICAM- 1 expression, as ICAM- is one of several ligands required
for T-cell adherence and activation. Cutaneous and ocular
melanocytes were expanded in culture using a mitogen-rich
MCDB 153 medium. Five to ten days before ICAM-1 analysis,
mitogens were removed from the medium, as this was necessary to
demonstrate any response to a-MSH. Unstimulated melanocytes
had constitutively low ICAM- expression, which was up-regu-
lated by the addition of TNF-oc (100 U ml-') for 24 h but unaf-
fected by the addition ofoc-MSH alone. However, co-incubation of
cells with oc-MSH and TNF-ox significantly reduced TNF-a-stimu-
lated ICAM-1 response by approximately 50% (10-1 M ca-MSH
reduced the response to TNF-ox by 35 ± I11%, n = 5); 10-8 M OC-
MSH by 57 ± 8%, n = 8). Maximal responses to oc-MSH were
usually seen between 10-10 and 10-8 M oc-MSH for cutaneous
melanocytes. In ocular melanocytes, preliminary data showed that
10-"' M cx-MSH reduced the ICAM response to TNF-a by 55% in
one experiment but only by 5% in a second. IBMX mimicked the
cx-MSH response by significantly reducing TNF-cx-stimulated
ICAM-1 expression in both cutaneous and ocular melanocytes.
This implicates the involvement ofcyclic AMP in the mechanism.
Present data strongly suggest that x-MSH has the potential to
oppose the actions of inflammatory cytokines in melanocytes. We
suggest that this is probably part of the normal spectrum of the
biological actions of cx-MSH in skin and possibly the eye.
Melanoma cells are known to produce cx-MSH (and related POMC
peptides). If a similar response to ax-MSH is retained in metastatic
melanoma cells, this could oppose the action ofcytokines released
from the immune cells.
Coexpression of bcl 2 with herpes
simplex virus thymidine kinase in tumour
cells increases non-apoptotic cell death
on ganciclovir treatment
AA Melcher', MD Jacobson2, and RG Vile'
'Imperial Cancer Research Fund Molecular Oncology Unit, RPMS,
Hammersmith Hospital, Du Cane Road, London, W12 ONN; 2MRC
Laboratory for Molecular Cell Biology, UCL, Gower Street, London, UK
We have previously demonstrated that killing tumour cells in vivo
with the HSVtk/ganciclovir (GCV) system generates anti-tumour
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immunity. However, the strength of this immunity differs between
cell lines; for example, B16tk+ tumours uniformly generate
increased protection against parental cell rechallenge (40-70%
protection) compared with CMT93tk+ tumours (10-20% protec-
tion). While investigating the mechanisms involved in these
effects, we observed that GCV-mediated cell killing of the B16
melanoma cell line occurs predominantly via necrosis (<1% of
apoptotic cells per field after 48 h of GCV treatment in vivo). In
contrast, killing of the colorectal CMT93 cell line occurred with
increased levels of apoptosis (20% of cells per field). These find-
ings were confirmed by studying the mechanisms ofcell killing in
vitro using DNA ladders, EM and propidium iodide staining at
several time points after GCV treatment. Therefore, we proposed
that necrotic cell death in vivo may provide a potent immunostim-
ulatory signal that serves as a 'danger' signal to allow the breaking
of tolerance to tumour antigens. Hence, the degree to which
HSVtk killings leads to necrotic or apoptotic cell death may influ-
ence the subsequent strength of the anti-tumour immunity.
To test this hypothesis, we transfected the CMT93tk line with a
retrovirus encoding bcl 2 in an attempt to block apoptotic cell
death during HSVtk/GCV killing. A population ofCMT93tk cells,
in which a proportion of cells express bcl-2 by FACS, are still
sensitive to GCV in vitro but show greatly reduced amounts of
apoptotic cell death as judged by DNA ladders and propidium
iodide staining. Data will be presented on the use of these cells in
in vivo experiments to determine whether the immunogenicity
generated by GCV killing ofthe bcl-2+ cells is greater than that of
the parental CMT93tk line. The implications of these findings for
the development ofthe 'danger' hypothesis in cancer immunogene
therapy will be discussed.
Concordance between epithelial tumour
cell metabolic activity and susceptibility
to chemo- and radiosensitivity
AME Nouri', MV Russell', H CannelF, AMI Paris3,
and RTD Oliver'
Departments of Medical Oncology, 2Maxillofacial Surgery and 3Urology,
London Hospital, London El1 BB, UK
Colorimetric and immunocytochemical staining techniques were
used to assess the influence of hyperthermia and, in parallel, the
relevance of epidermal growth factor receptor (EGFR) expression
to radio- and chemosensitivity of four human epithelial tumour
cell lines of different origins.
The results showed that: (I) all cell types showed inhibition of
metabolic activity as measured by optical density (OD) in response
to cisplatin or gamma radiation in a dose-related manner; (2)
increase in culture temperature or stimulation of cells expressing
high intensity of EGFR with EGF resulted in an increase of
cellular metabolic activity by as much as 60% (the stimulatory
activity ofEGF was significantly decreased when temperature was
increased from 37°C to 400C); (3) addition of EGF to cells
increased their susceptibility to cisplatin by up to 40%; and (4)
increasing temperature from 37°C to 40°C resulted in an increased
sensitivity ofcells to cisplatin and radiation by up to 35% and 25%
respectively.
These results indicate the relevance of status of cell aggressive-
ness as indicated by their high levels of metabolic activity and
their responsiveness to radio- and chemotherapy. The induction of
hyperthermia should increase the efficacy of cancer treatment
modalities. This will make it possible to treat patients with lower
concentration of drugs to achieve the same level of response. In
addition, the finding that the higher-EGFR-expressing tumour cell
lines responded more efficiently to treatment when exposed to
EGF might provide a lead for the better selection of patients for
chemotherapy.
DNA Interaction with polymeric vesicles -
consequences for the transfection
efficiency (in vitro)
A Schatzlein', M Brown2, S. Siddique&, IF Uchegbu2,
and L Tetley3
'CRC Department of Medical Oncology, Beatson Laboratories, University of
Glasgow, Glasgow G61 1 BD; 2Department of Pharmaceutical Sciences,
University of Strathclyde, Glasgow Gl JXW; 3EM Centre Biological
Laboratory, ILBS, University of Glasgow; Glasgow, G12 8QQ, UK
Although various promising strategies for the genetic therapy of
cancer have been proposed recently, the specific and efficient
delivery of the genetic material into (cancer) cells still remains a
major hurdle. Viral vectors, e.g. adenoviruses, have been shown to
be quite efficient and even specific vectors, but virus-related
toxicity and immune response impose severe restrictions on their
(repeated) use (Blaese et al, 1995, Cancer Genie Therapy 2: 291).
However, the efficiency of non-viral vectors, most of them based
on cationic amphiphiles (Gao and Huang, 1995, Gene Therapy 2:
710) and polymers (Stankovics et al, 1994, Humnan Genie Therapy
5: 1095), remains unsatisfactory for many in vivo applications. We
advocate the use of modular non-viral gene delivery systems that
consist of a combination of tools that fulfil dedicated functions.
Vesicles are one option as basis for such modular systems.
Novel polymeric vesicles have been prepared from prepolymer-
ized amphiphiles, such as glycol chitosan (degree of polymeriza-
tion - 800). Their biocompatibility was studied by a haemolysis
assay and MTT assay (Plumb et al, 1989, Caincer Res 49: 4435)
with three human cell lines (A2780, A549 and A431). The inter-
action with DNA was studied in combination with cationic
amphiphiles (e.g. DOTAP, DODAB) and alone. The morphology
of the complexes was characterized by freeze fracture EM. The
degree of DNA condensation was determined by ethidium
bromide exclusion. Zeta potential measurements and gel retarda-
tion assays were used to study their net charge and electrophoretic
mobility (zeta potential, gel retardation). The transfection effi-
ciency of the DNA-carrier complexes was studied with reporter
gene constructs (pCMV-Sport-pGal, pEGFP-Cl) in A549, A2780
and A431 cells in vitro.
The self-assembly of preformed polymers into vesicles was
assumed to depend on the decoupling ofthe polymer backbone from
the membrane-forming amphiphile. However, we have found that
carbohydrates, such as glycol chitosan and other biopolymers, once
modified by the attachment offatty acidpendantgroups (GP41), may
self-assemble and form unilamellar polymeric vesicles in the
presence of cholesterol. Such systems may be produced from the
hydrophobic modification ofa wide variety ofcarbohydrates, such as
starch, dextran and other oligosaccharides. Such vesicles may be
useful drug carriers as they have an inherently greater membrane
stability then conventional vesicles. They were stable and retained
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approx. 60% of their drug content (water-soluble glycopeptide,
Mr 1500) over a period of more than 5 weeks. GP41 vesicles did not
induce significant haemolysis at erythrocyte/GP41 ratios of
300-30:1 w/w (DOTAP 80-100% haemolysis) and were biocompat-
ible with human cells (A2780, A549 and A431), with no toxicity
evident at concentrations ofGP41 < 150 gg ml-'. DNA condensation
by GP4I/cholesterol polymeric vesicles was only moderate (20-40%
at amphiphile/DNA molar ratios of 0.25-5:1) compared with a
condensation of approx. 90% achieved by DOTAP (ratio 2.5-5:1).
When combined with the cationic amphiphile DODAB, however,
DNA/DODAB-GP41/cholesterol complexes were able to achieve a
condensation of 90%. Cationic amphiphiles were significantly less
toxic when combined with polymeric vesicles. Polymeric vesicles
were not able to transfect mammalian cells in vitro when used alone
but could be tailored to deliver DNA to cells in combination with
cationic amphiphiles. The presence of cationic amphiphiles is prob-
ably necessary to improve DNA condensation but may also influence
the endosomal escape of the DNA carrier complex later on. The
combination of polymeric vesicles with other compounds into a
'shuttle' vector may help to improve non-viral gene delivery in vivo.
Influence of tumour cell proliferation on
expression of cellular phosphatases
AME Nouri, AANM Dabare and RTD Oliver
Medical Oncology, London Hospital, London El 1 BB, UK
Cytometric, immunocytochemical, biochemical and colorimetric
(MTT) assays were used to assess the influence ofcell proliferation
on the expression ofcellular alkaline phosphatases (ALP) in estab-
lished human tumour cell lines of epithelial origin. These enzymes
are increasingly being recognized as important markers for moni-
toring tumour cell behaviour in some human malignancies.
The results showed that:
(1) The degree of ALP differs widely in various tumour cell
lines. Based on biochemical analysis, the profile of ALP fell
mainly into two categories: (a) low expressing (MW 72 kDa,
most probably placental type ALP), such as Hep2 and KB
(head and neck); and (b) those that expressed both low- and
high-molecular-weight (MW 95 kDa) bands, i.e. mainly
tumours oftestis, including Tera II and Ep2012.
(2) In all the cases, treatment of tumour cell lysates with heat
before biochemical analysis showed the disappearance ofthe
higher MW and sharpening ofthe lower band.
(3) Exposure of tumour cells to epidermal growth factor (EGF)
led to an increased cellular proliferation as measured by
MTT assay. In parallel, there was a concomitant decrease in
ALP bands as assessed by biochemical method.
(4) Cytometric analysis ofcells comparing expressed ALP as
detected by monoclonal antibody specific for placental-type
ALP showed that there was as much as 77% decrease in the
expression when cells were exposed to EGF in culture. In
addition, this was only observed in cells expressing high-
intensity EGFR.
These findings demonstrate the differential expression ofALP in
tumour cell lines of different origins. The results also indicate that,
as the status ofcell proliferation increased, there was a concomitant
decrease in the levels of ALP expression. These issues raise the
question as to whether the differential expression of EGFR and
ALP in tumour biopsies may provide an indication of tumour
aggressiveness, a study that is currently under investigation.
The cell death-cell cycle interface:
biochemical mechanism and
physiological role
HJM Brady1, 0 Williams', A Berns2, D Kioussis'
and G Gil-G6mez2
'Division of Molecular Immunology, NIMR, Mill Hill, London NW7 1AA;
2Division of Molecular Genetics, Netherlands Cancer Institute, Plesmanlaan
121, 1066 CX Amsterdam, The Netherlands
There are no decisions more fundamental to the cell than whether
to divide or to die? When cell division becomes deregulated,
tumour formation and cancer can be the result. Furthermore, if
cells lose the ability to die by apoptosis in response to normal
physiological cues, this may also contribute to tumour formation.
Therefore, the possibility that the pathways of cell cycle and
apoptosis may have an overlapping biochemical mechanism is of
great fundamental interest, as well as having potentially important
therapeutic implications for disease, including cancer.
We have approached the cell cycle-apoptosis interface from our
work on the Bax and Bcl-2 molecules, which regulate cell death. We
have shown that, although p53 regulates expression of the bax gene,
overexpression ofBax in p53-/- thymocytes is insufficient to restore
the apoptosis pathway lost in the absence ofwild-type p53 (Brady et
al, 1996a, EMBO 15: 1221). We further showed that, in our bax trans-
genic mice, T-cell development is severely disrupted, which implies a
role for BaxIBcl-2 in the production of a fully functional immune
system. Using T cells from bax and bcl-2 transgenic mice, we also
showed that Bax accelerates while Bcl-2 slows down entry into the
cell cycle (Brady et al, 1996b, EMBO 15: 6991). We have now shown
that resting cells triggered to die down-regulate p27KiPl, an event
normally associated with cell cycle entry. We also show that Bax/Bcl-
2 can directly influence the extent of p27Kip1 degradation and hence
the activity of cyclin-dependent kinase (Cdk) 2. Specific pharmaco-
logical inhibitors of Cdk2 activity can completely block various
forms of apoptosis but not that induced via the CD95 (Fas) receptor.
We show that the activity ofCdk2 in apoptosis is not associated with
its canonical cyclins (A and E) as during the cell cycle. We also
describe experiments that directly prove the influence of Cdk2
activity alone as an effector of apoptosis. Using fetal thymic organ
culture from transgenic mice in the presence ofvarious Cdk2-specific
inhibitors, we show the importance ofCdk2 activity in various physi-
ologically important cell death pathways, such as antigen-driven
negative selection. Bcl-2 acts as an oncogene, and recently Bax has
been shown to be a tumour-suppressor gene. Bax/Bcl-2 ratios have
been shown to be good prognostic indicators of various forms of
cancer. We discuss our cell cycle-cell death data in the light ofthese
facts and their therapeutic implications for cancer treatment.
The tpr gene is overexpressed and
inducible in ovarian cancer cells exposed
to carboplatin
P Gilmore, MT Cairns, P White, S Church and PG Johnston
Department of Oncology, Belfast City Hospital, BT9 7AB, UK
The development of platinum resistance is a common occurrence
in ovarian cancer. We have used the differential display (DD)
technique (Liang and Pardee, 1992, Science 257: 967) on paired
platinum-sensitive and -resistant ovarian epithelial cell lines
(PEAU/PEA2 and PEO1/PEO4) to identify genes with a putative
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involvement in the development of platinum resistance. Growth
inhibition assays showed that PEA2 cells (IC50 1.5 x 10-6 M ± 0.17)
were ten times more resistant to carboplatin (CBDCA) than PEAl
(IC50 1.97 x 10-7 M ± 0.098, while PEO4 cells (IC50 6.3 x 10-6 M
± 0.86) were 40 times more resistant to CBDCA than PEO1 (IC50
1.99 x 10 6 M ± 0.22). Differential display patterns were obtained
from PEAl/PEA2 and PEOU/PEO4 cells grown under normal
culture conditions and after a time-course (1, 6 and 24 h) of
CBDCA exposure. Northern blotting confirmed the differential
expression ofa candidate gene identified by DD, which hybridized
to a specific mRNA of 3.5 kB in size. Sequence analysis revealed
homology (92%) to the tpr (translocated promoter region) gene
sequence (Mitchell and Cooper, 1992, Oncogene 7: 383).
Expression of the tpr-homologous ('tpr-hom') gene was found to
be increased more than threefold in untreated platinum-resistant
cell lines (PEA2 and PEO4) compared with sensitive cell lines
(PEA1 and PEOG) and was induced over a time-course of acute
exposure to IC50 concentrations of CBDCA in the same cell types
(by threefold and 12-fold in PEA2 after 6 h and 24 h, respectively,
and by sixfold and 38-fold in PEO4), while remaining unchanged
from control levels in the sensitive cells. These data suggest that
tpr may play an important role in the development of platinum
resistance, which will be further investigated via transfection of a
full-length tpr cDNA (clone obtained courtesy of Dr L Gerace)
into the sensitive (PEAl and PEO1) types to determine its effect
on sensitivity/resistance phenotype.
The development of a quantitative
RT-PCR for thymidylate synthase from
formalin-fixed and paraffin-embedded
tissue specimens
S Church, P Gilmore, P White and PG Johnston
Department of Oncology, Belfast City Hospital, BT9 7AB, UK
The expression level ofthe thymidylate synthase (TS) enzyme has
been established as a predictor of response to 5-fluorouracil (5-
FU)-based therapy. Patients whose tumours express low levels of
TS respond significantly better than those with high TS levels.
Quantitative reverse transcriptase-polymerase chain reaction (RT-
PCR) and immunological quantitation have been adopted as tech-
niques to measure TS levels in tumour samples. In an attempt to
improve the applicability ofthese techniques, we have developed a
novel RT-PCR technique for TS quantitation using formalin-fixed
and paraffin-embedded (FFPE) tissue.
Total RNA was isolated from FFPE sections ranging in size from
16 to 64 microns. Spectrophotometrically detectable RNA was
obtainedusing 30-micron amounts ofstarting material. The amounts
ofRNA obtained ranged from a minimum of0.5 ,ug to a maximum
yield of8 gg. The ,-actin gene was chosen as the internal PCR stan-
dard, using primer sequences designed to generate a 230-bp
amplicon; the TS-specific primers yield a 250-bp amplicon. Both
the 1-actin and TS target sequences were readily amplifiable from
cDNAs generated from archival RNA samples. That these products
were deiived from cDNA rather than genomic DNA contamination
was confimed by the use of primers for the thymidine kinase (TK)
gene, which span an intron and yield a 96-bp amplicon from cDNA
samples and a 206-bp amplicon from genomic DNA. Optimization
experiments determined that aPCR cycle numberofbetween 22 and
25 rendered both the 3-actin and TS products in the log phase of
amplification. The procedure for performing quantitative RT-PCR
on RNAs isolated from archival tissue has been optimized and is
suitable for use in further investigations that will compare levels of
TS determined by RT-PCR with immunohistochemical analysis
from the same pathological tissue sample.
Application of the amplification refractory
mutation system (ARMSTM) with real-time
fluorescence detection to assess K-ras
mutations in bronchoalveolar lavage (BL)
specimens for early lung cancer
detection
FM Scott1,2, SJ Clayton3, KCallaghan3, WPrime1,2,
M Walshaw4, L Turnbull5, G Ellison3, JC Fox3 andJK Field12
'Roy Castle International Centre for Lung Cancer Research, 200 London
Road, Liverpool L39TA; 2Molecular Genetics and Oncology Group, Clinical
Dental Sciences, University of Liverpool, L69 3BX; 3Zeneca Diagnostics,
Gadbrook Park, Northwich, Cheshire CW9 7RA; 4Cardiothoracic Centre,
Broadgreen Hospital, Thomas Drive, Liverpool L14 3LB; 5Department of
Pathology, University of Liverpool, L69 3BX, UK
Mutations of the ras family of oncogenes are the most frequently
observed genetic lesions in a number of human malignancies.
About 80-90% of activating mutations of the K-ras gene occur at
codon 12 or 13 in human non-small-cell lung cancer. K-ras muta-
tions therefore provide a screening target for early detection of
lung cancer. Seven ARMS tests have been developed for acti-
vating mutations at codons 12 and 13 of K-ras. Application of
ARMS to lung tumour DNA has previously identified 9% of non-
small-cell lung cancers as possessing K-ras mutations (Neville et
al, 1995, Int J Oncol 7: 511). One hundred and eleven BL DNA
samples from patients with lung-related problems were analysed
for K-ras mutations; 75 of the samples were initially analysed by
gel electrophoresis of ARMS-generated PCR products and three
were identified with K-ras mutations (codon 12 Gly-*Asp).
Although these specimens were negative for cancer by cytology,
one was from a patient with a diagnosis of secondary adenocarci-
noma of the lung and two were from patients with non-cancer
diagnoses. The other 36 BL DNAs were analysed using homoge-
nous fluorescence-based detection ofARMS-generated PCR prod-
ucts in a real-time format. Four mutations (three Gly-*Cys, one
Gly-3Val at codon 12) were detected in these samples. Two were
in BL specimens from patients diagnosed with lung adenocarci-
noma, and these specimens also contained adenocarcinoma cells
by cytology. The other two were from patients with a diagnosis of
lung carcinoma, but with no cancer cells detected by cytology. The
results of the ARMS analyses will be presented and the potential
of K-ras testing for lung cancer screening will be discussed.
Microsatellite instability and loss of
heterozygosity in bronchial lavage
specimens
TLiloglou1 2, G Xinarianos12, WPrime 2, M Walshaw3,
L Turnbull4 andJKFieldl12
'Roy Castle International Centre for Lung Cancer Research, Liverpool
L3 9TA; 2Molecular Genetics and Oncology Group, Department of Clinical
Dental Sciences, The University of Liverpool, Liverpool L69 3BX; 3The
Cardiothoracic Centre, Broadgreen Hospital, Liverpool L14 3PE; 4Department
of Pathology, The University of Liverpool, Liverpool L69 3BX, UK
British Journal ofCancer (1998) 78(2), 141-158 0 Cancer Research Campaign 1998148 Abstracts
Genomic instability is now considered to be a hallmark of cancer.
Analysis ofmicrosatellite markers in tumour tissue compared with
its normal counterpart has become the most widely used method to
determine genomic instability in the form of microsatellite alter-
ations (MA) or loss of heterozygosity (LOH). Genomic instability
has been found in 42-49% ofnon-small-cell lung cancers (Miozzo
et al, 1996, Cancer Res 56: 2285; Neville et al, 1996, Int J Oncol
9: 533). We studied 90 bronchial lavage specimens from individ-
uals with suspected lung cancer using 12 microsatellite markers.
Genomic instability was found in 15 of 43 (35%) patients with
lung cancer, however it was also found in 11 of47 (23%) patients
with no cytological or radiological evidence of bronchial
neoplasia. We have also demonstrated the same genomic insta-
bility in a number ofbronchial lavage specimens and in the corre-
sponding tumours. These results demonstrate the potential of MA
in bronchial lavage specimens as an early detection marker.
This research is supported by the Roy Castle Cause for Hope
Foundation.
Telomerase activity in lung cancer and
human bronchoalveolar lavage fluid
G Xinarianosl,2, FM Scott1l2, WPrimel12, M Walshaw&,
L Turnbull4 andJK Field' 2
'Roy Castle International Centre for Lung Cancer Research, 200 London
Road, Liverpool L39TA; 2Molecular Genetics and Oncology Group, Clinical
Dental Sciences, University of Liverpool, L69 3BX; 3Cardiothoracic Centre,
Broadgreen Hospital, Thomas Drive, Liverpool L14 3LB; 4Department of
Pathology, Duncan Bldg., University of Liverpool, L69 3BX, UK
The maintenance oftelomeres, or chromosome ends, is essential to
the progression of cells through a normal, mortal life span. In
tumour tissues and immortalized cells, telomeres are maintained
by telomerase, a ribonucleoprotein polymerase, at lengths that are
generally shorter than normal tissue. Telomerase is expressed in
most cancers and absent in most normal tissues. This includes
about 80% ofprimary lung tumours, about 93% ofbreast cancers,
90% of head and neck squamous cell carcinomas and 88% of
cervical cancer specimens. We have measured telomerase activity
in lung cancer cell lines and lung tumours using the telomerase
repeat amplification protocol (TRAP) (Kim et al, 1994, Science
266: 2011). Four of four lung cancer cell lines and 12 of 15 lung
tumours examined contained telomerase activity, which was not
detectable in matching normal tissue. In order to investigate telo-
merase as a potential early detection marker for lung cancer, the
enzyme will need to be measured in bronchoalveolar lavage (BL)
or sputum specimens. Three of 19 (16%) BL specimens from
patients undergoing bronchoscopy for diagnosis of lung cancer
and for other reasons had detectable telomerase activity by the
TRAP, applied in a radioactive or non-radioactive format. The
possibility of inclusion of telomerase in a panel of lung cancer
early detection markers will be discussed.
This research is supported by the Roy Castle Cause for Hope
Foundation.
A 'new' glioma-associated cell surface
glycoprotein
KMulligan', D McCormick2, E Dermott3, B Wisdom4,
B Radotral and M Mirakhur'
'Neuropathology, 20ncology, 3Microbiology and 4Biochemistry, The Queen's
University of Belfast, Belfast BT9 7AB, UK
While malignant gliomas rarely metastasize, they characteristi-
cally exhibit diffuse and extensive invasion into normal brain
parenchyma. This invasive capacity is primarily responsible
for the failure of current therapies to prevent tumour recurrence.
Glioma invasion is a complex process involving partial
degradation of the extracellular matrix (ECM) and cell-cell
and cell-ECM interactions mediated by cell surface adhesion
molecules.
As part of an investigation of glioma adhesion molecules,
monoclonal antibodies were generated to proteins expressed by an
anaplastic astrocytoma cell line. One of the hybridomas produced
secretes an antibody (MQI) that recognizes two previously unde-
scribed mammalian glycoproteins ofmolecular weight 50 kDa and
200 kDa. N-terminal sequencing revealed that both proteins have
the same N-terminal amino acid sequence and that they share 74%
homology with a micro-organism adhesion protein.
Immunoprecipitation demonstrated that the 200-kDa protein
was expressed on the cell surface of astrocytoma cells in vitro.
Immunocytochemistry showed expression of the MQ1 surface
protein on a range of fetal astrocytes and astrocytoma cell lines in
vitro, and flow cytometry indicated that the level of expression
correlated with astrocytoma malignancy and inversely correlated
with fetal astrocyte maturity.
Immunohistochemistry on histologically normal and neoplastic
brain tissue demonstrated that in the central nervous system (CNS)
MQ1 protein expression is restricted to cells of astrocytic lineage,
and that reactive astrocytes and astrocytomas are strongly
immunoreactive for the MQ1 proteins.
In summary, the 200-kDa MQ1 protein is a previously unde-
scribed glioma-associated cell-surface glycoprotein, with proper-
ties suggesting that it may be an adhesion molecule with a role in
fetal development and neoplasia in the CNS.
Antiproliferative effects of bioactive
peptides secreted by frog skin towards
human breast cancer cells in vitro
HW van den Berg1, C Shaw2, M Lynch1 and PJohnston1
Departments of 'Oncology and 2Medicine, The Queen's University of Belfast
Drugs derived from natural products play an important role in the
treatment of disease, including cancer. However, until recently,
large-scale, systematic and rational drug discovery has not been
undertaken. We have initiated studies ofthe antiproliferative prop-
erties of natural peptides from a number of species, including
those contained in dermal venom components offrogs.
The antiproliferative effects of three purified and sequenced
peptides (frog mellitin, PEC and PLR) have been investigated
using a panel of human breast cancer cell lines (ZR-75-1, ZR-PR-
LT, ZR-75-9al, MCF-7 and LY2), which differ in their anti-
oestrogen sensitivity, steroid hormone receptor profile and in their
expression of epidermal growth factor receptors (EGFR) and
insulin-like growth factor-I receptors (IGFR). Inhibition of cell
proliferation was assessed over a 9-day period of growth in
medium supplemented with 5% fetal calf serum in 96-well plates
using the MTT colorimetic assay.
Frog mellitin failed to significantly influence the proliferation of
any of the cell lines investigated. PEC at concentrations ranging
from 1010 to 108M stimulated the proliferation of oestrogen-
dependent ZR-75-1 and tamoxifen-resistant LY2 cells, while
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failing to consistently influence the growth ofthe other cell lines in
the study. In contrast, PLR in the concentration range 10-12-10-8 M
inhibited the proliferation of all the cell lines studied. A reduction
in cell number was observed 3, 6 and 9 days after treatment with
drug replenishment on days 3 and 6. In ZR-75-1, MCF-7 and the
tamoxifen-resistant ZR-75-9al lines, this inhibition was modest
(20-40%), non-dose dependent and cells showed signs ofrecovery
at day 9. However, inhibition of proliferation of ZR-PR-LT and
LY2 cells was clearly dose dependent, with IC590 values at day 9 of
approximately 10-1 M. Interestingly, these cell lines have reduced
numbers of EGFR in comparison to their respective parent lines.
This may reflect receptor occupancy, raising the possibility that
PLR may act in part by interfering with EGF/TGF alpha action at
the EGF receptor.
We conclude that PLR shows promise as an antiproliferative
peptide, and that the effects observed are unlikely to be non-
specific as response was variable among the cell lines studied.
Further studies will be designed to determine the antiproliferative
mechanism of PLR and assess its ability to bind to specific cell
membrane-associated receptors.
The expression of desmoglein-2 in
primary breast cancer and its relation to a
series of prognostic markers
EL Davies', JMW Gee', RA Cochrane1, RI Nicholson2,
AKSharma', WG Jiang' and RE Mansell
'Department of Surgery and 2Tenovus Cancer Centre, University Hospital of
Wales, Cardiff, UK
The presence of local invasion and distant metastasis is of prime
importance to patients presenting with primary breast cancer.
Several adhesion molecules (i.e cadherins) have been shown to act
as metastatic suppressor molecules. Desmoglein 2 (Dsg2) is a novel
glycoprotein forming a subfamily ofthe cadherin group ofadhesion
molecules. Its role as a potential metastatic suppressor molecule has
been demonstrated in transitional and squamous cell carcinomas and
in our recent breast cancer in vitro data. However, its expression and
role in breast cancer in vivo has yet to be established.
The aims of this study were to demonstrate and establish the
level of immunohistochemical (IHC) expression of Dsg2 in breast
cancer specimens (n = 68) as well as in ductal carcinoma in situ
(DCIS) (n = 3), tumour-associated normal (TAN) (n = 11) and
normal breast tissue (n = 9). Secondly, we compared the IHC level
of Dsg2 expression and a series of prognostic markers [oestrogen
(ER) and progesterone (PR) receptors, Ki-67, epidermal growth
factor receptor (EGFR), grade and size of tumour, lymph node
involvement and menopausal status].
The results revealed that the majority of cancers (98.5%)
demonstrated membranous staining for Dsg2. However, the Dsg2
expression was significantly reduced in breast cancer compared
with normal and TAN (P < 0.0001) but not with DCIS (P = 0.067).
A significant inverse relationship between tumour size and Dsg2
expression was demonstrated (P = 0.012), but no correlation could
be shown between Dsg2 level and the other prognostic markers.
These results suggest that Dsg2 may have a potential in local
breast cancer progression, but have not provided evidence for a
metastatic suppressor role for Dsg2.
Effects of in vivo interleukin-12 (IL-12)
administration in renal cell carcinoma
patients
D Stark, RE Banks, RW Carter, MA Forbes, S Hallman,
J Stanley, PJ Selby and PM Patel
ICRF Cancer Medicine Research Unit, St James's University Hospital, Leeds
LS9 7TF and UK
Six patients (three male and three female) with inoperable renal
cell cancer received recombinant human IL-12 as part of a multi-
centre phase II European trial. After dose escalation, 0.1, 0.5,
1.25 tg/kg-' s.c. weekly over the first 3 weeks, these were up to
three further cycles of treatment, each consisting of three weekly
injections (1.25 ,ug kg-' s.c.) and one rest week. Four patients had
no significant clinical problems. One patient developed pulmonary
oedema during a blood transfusion. One patient developed the
nephrotic syndrome. The relationship of these events to IL-12 is
unknown and under investigation. One patient had a WHO grade 3
or higher rise in their liver biochemistry, and two had a grade I
elevation. Three patients had WHO grade I chills and one of the
six had grade I oral mucositis. Two patients stopped treatment
because ofadverse events, two because ofdisease progression, and
two had stable disease at the end of treatment.
Serum level ofIL-12 ranged from 40 to 450 pg ml -i, by ELISA,
48 h after dose one, and returned to under 150 pg ml-1 by 24 h.
PBMC subpopulations and lymphocyte activation were measured
by flow cytometry. Increased NK and LAK activity were demon-
strated after IL-12. THI/TH2 cytokine balance was assessed by
three-colour cytometric analysis of intracellular cytokines. IFN-y




R Satchi and R Duncan
Centre for Polymer Therapeutics, The School of Pharmacy, University of
London, London WC1N 1AX, UK
Improvements in cancer chemotherapy, particularly for the treat-
ment of common solid tumours, have been difficult to realize.
PDEPT is a novel approach using polymeric prodrugs and polymer-
bound enzymes to improve cancer therapy. The concepts of
antibody-directed enzyme prodrug therapy (ADEPT) and gene-
directed enzyme prodrug therapy (VDEPT) are already well estab-
lished and have demonstrated improved therapeutic activity in
animal models and pilot human studies. However, both approaches
have a number of inherent limitations, such as immunogenicity,
difficulty in optimization of the dosing schedule because of the
plasma half-life of antibody enzymes, the need to use a clearing
antibody and the inherent dangers associated with a viral vector.
PDEPT uses a polymer-enzyme conjugate that accumulates
selectively in solid tumour tissue by the enhanced permeability
and retention (EPR) effect to selectively activate a polymeric
prodrug that can likewise accumulate preferentially in the tumour.
The polymeric prodrug can be designed to contain a potent cyto-
toxic agent covalently bound to polymer via a linker designed for
cleavage by the enzyme present in the polymer-enzyme
conjugate. PDEPT has the potential to overcome the problems
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associated with ADEPT and VDEPT. N-(2-hydroxypropyl)metha-
crylamide (HPMA) co-polymer enzyme conjugates will have little
or no immunogenicity (Flanagan et al, 1990, J Bioact Compat
Polymers 5: 151), and HPMA co-polymer-doxorubicin conjugates
have already shown promise in an early clinical trial (Vassey et al,
1996, Ann Oncol 7: 97). In this study, we have prepared and
characterized HPMA polymer conjugates containing ,-lactamase
and cathepsin-B as model enzymes, with a yield of 28%.
Activity of free and conjugated enzymes was assayed using low-
molecular-weight prodrugs (benzylpenicillin for 3-lactamase and
Bz-Phe-Val-Arg-p-nitroaniline for cathepsin-B) as well as on
high-molecular prodrugs such as HPMA-Gly-Phe-Leu-Gly-
doxorubicin (PKl) for cathepsin-B. Both retained enzyme activity
after polymer conjugation giving V,nax 0.2 nM s-' unit-' and Km 0.1.
Radiolabelled P-lactamase andHPMA-Gly-Gly-p-lactamase were
administered i.v. to C57 mice bearing s.c. B16Fl0 melanoma for
comparison of their pharmacokinetics. Polymer-enzyme conju-
gate showed a retention time of 3.6-fold in the blood with respect
to the free enzyme and higher site-specific passive capture through
the EPR effect giving twofold increase in accumulation of the
conjugate compared with free enzyme in the tumour.
Preferential replication of an El B-
attenuated adenovirus in drug-resistant
ovarian tumour lines with defective
mismatch repair and loss of p53 function
YTKim, I Ganley, M Illand, S Kaye and R Brown
CRC Department of Medical Oncology, CRC Beatson Laboratories, Glasgow
G61 1BD, UK
Compared with wild-type Ad2 virus, an adenovirus lacking E1B
55-kDa gene expression (ONYX-015) has significantly reduced
replication in the wild-type p53-expressing human ovarian adeno-
carcinoma A2780 cell line. We have measured virus replication
using plaque-forming assays and expression of viral hexon
proteins in infected cells. Introduction ofa mutant p53 (codon 143,
Val to Ala) into these A2780 cells causes loss ofp53 function and
increased replication of ONYX-015. Defective mismatch repair
and loss of p53 function is associated with resistance to the anti-
cancer drug cisplatin in this ovarian carcinoma cell line model
(Anthoney et al, 1996, Cancer Res, 56: 1374). Increased ONYX-
015 replication is observed in three independent cisplatin-resistant
derivatives of A2780. These cisplatin-resistant derivatives have
loss expression of the hMLH1 mismatch repair gene. Restoration
of hMLH1 gene expression by chromosome 3 transfer into a
cisplatin-resistant derivative A2780/cp7O restores cisplatin sensi-
tivity to near A2780 levels. However, the cells re-expressing
hMLH1 are equivalently permissive for ONYX-015 replication as
the parental hMLH1-deficient line and to chromosome 2 transfer
controls. This lack of restoration of p53 function by hMLH1 re-
expression is supported by lack of p53 transcriptional activity, as
measured using expression-reporter constructs containing p53
consensus binding sites. The cells re-expressing hMLH1 do,
however, regain a cisplatin-induced G2 cell cycle arrest,
suggesting that coupling ofdamage to G2 arrest by hMLH1 may be
a more important determinant of mismatch repair-associated
cisplatin sensitivity than p53-mediated events in these cells.
Up-regulation of the expression of
hepatocyte growth factor activator
(HGFA) in breast cancer
S Hiscox, EL Davies and WG Jiang
Department of Surgery, University of Wales College of Medicine, Heath Park,
Cardiff, S. Wales, CF4 4XN, UK
Hepatocyte growth factor (HGF) is a pleiotropic growth factor that
enhances the metastatic potential ofbreast cancer cells in vitro and
thus may promote tumour growth and metastatic spread in vivo.
HGF is secreted as an inactive single-chain form that is activated
by the action ofthe serine protease HGFA in vivo.
The aim of this study was to examine the expression of HGFA
in a series of breast cancer tissue pairs (tumour tissue and back-
ground normal tissue; number of pairs = 14). Total tissue protein
was extracted from these tissues and subject to SDS-PAGE.
Immunoprobing was then performed with anti-HGFA antibodies.
We observed the expression of a 34-kDa protein in all tissues;
this protein corresponded to the active form of HGFA, produced
from the inactive pro-HGFA by enzymic cleavage. This active
HGFA protein was greatly up-regulated in 11 of 14 (78%) tumour
tissues compared with their normal tissue counterparts. In 5 of 14
sample pairs (35%), a 97-kDa protein was detected corresponding
to the inactive precursor form of HGFA (pro-HGFA). In each
sample in which pro-HGFA was detected, expression was greater
in the normal tissues than in their tumour counterparts.
We conclude that levels of active HGFA are elevated in breast
tumour tissue, which may arise by the up-regulation ofpro-HGFA
to active-HGFA cleavage. Elevated levels of HGFA in tumour
tissue may raise the levels of HGF itself within these tissues and
thus promote tumour spread.
A novel flow cytometric study of antigen
expression to characterize cell type
RL Loveday, J Greenman, MJ Kerin andJRTMonson
Department of Surgery, Academic Surgical Unit, University of Hull,
Cottingham Road, Hull HU6 7RX, UK
Characterization of cell types has traditionally been by immuno-
histochemistry, a non-quantitative technique. In this study, a novel
flow cytometric technique has been used to allow analysis of
surface and intracellular antigen expression in a series of
colorectal and breast cancer cell lines. For analysis of intracellular
markers, cells were fixed with a weak formaldehyde solution and
then permeabilized with saponin. A panel of epithelial and fibro-
blast markers were assessed. These included BerEP4, EMA and
323A3 as cell surface epithelial markers and cytokeratin 19 as an
intracellular epithelial marker. To identify fibroblasts, a surface
fibroblast marker and intracellular vimentin were used. All of the
cell lines showed strong staining for cytokeratin, whereas variable
levels of the cell surface markers were found. As expected ZR751,
T47D, MCF7, BT20, HT29 and LOVO showed strong staining for
the three epithelial surface markers and cytokeratin and negative
staining for the fibroblast marker and vimentin. In contrast, MCF7
ADR showed strong staining for both surface epithelial and
fibroblast markers and also for vimentin and cytokeratin. LS180
showed better staining for 323A3 than the other epithelial surface
markers, whereas CACO2 showed weak expression of all surface
epithelial antigens.
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ZR751a MCF7 ADR LS180 CACO2
BerEP4 72b 63 49 10
EMA 92 74 2 5
323A3 83 78 81 9
Fibroblast 19 84 6 42
Vimentin 11 90 7 86
Cytokeratin 92 90 71 88
aT47D, MCF7, BT20, HT29 and LOVO produced similar results to ZR751.
bThese results are described as the percentage of positively stained cells.
The results indicate that the commonly used epithelial and
fibroblast markers are not adequate in discerning cell populations;
it appears that cytokeratin is the best marker for epithelial cells,
however strong staining for cytokeratin does not exclude the
presence of fibroblastic antigens.
In addition, when studying cell cycling, it was found that intra-
cellular staining with MIB 1 was far superior to Ki67 in assessing
cell proliferation.
Role of CD40 in anti-tumour immune
responses
AB Alexandroff, JA Ross and KJames
Department of Surgery, The University of Edinburgh, Lister Laboratories,
RIE, Edinburgh EH3 9YW, UK
CD40 plays a crucial role in co-stimulation, survival and apoptosis
of B and T cells and professional antigen-presenting cells. Despite
being first identified on bladder carcinomas, very little is known
about CD40 function in solid tumours. We examined the effect of
CD40-ligand (CD40L) on the expression ofcell-surface molecules
and cytokine secretion by bladder and pancreatic carcinomas.
Pure CD40L trimer induced marked ICAM-1 and FAS but not
MHC class II expression on CD40+ but not CD40- carcinomas
cells. It also induced IL-6 but not IL-12 or IL-4 production. In
control experiments, CD40L readily induced IL-12 in mono-
nuclear cells obtained from healthy donors.
The intensity of CD40 expression could be enhanced but not
induced by IFN-,y or patients' urine obtained after intravesical
immunotherapy. No constitutive or induced expression of
CD40L was observed on all cell lines studied. We have cloned
(and sequenced) CD40 and CD40L into the retroviral vector
pBabe.Puro. Currently, we are transfecting (CD40- CD40L-) y
carcinoma cell lines with CD40 and CD40L to establish whether
this could (a) render them sensitive to CD40L; (b) enhance co-
stimulation of lymphocytes reported by us previously.
ICAM-1 expression is essential for and correlates with cell-
mediated killing of bladder cancer. FAS is essential for FAS
ligand-mediated apoptosis of tumour cells. IL-6 is important for
the generation of tumour-specific cytotoxic lymphocytes. Our
results suggest that CD40-CD40L interactions may play an impor-
tant role in the triggering and enhancing of effective anti-tumour
responses.
This study was funded by the University of Edinburgh Faculty
of Medicine Cancer Research fund. CD40L was kindly provided
by Immunex. AB Alexandroff also acknowledges the receipt of a
BACR travel fellowship.
Cytogenetic determination of
chromosomal aberrations in breast
tumours
RL Loveday, J Greenman, JRTMonson and MJ Kerin
Department of Surgery, Academic Surgical Unit, University of Hull,
Cottingham Road, Hull HU6 7RX, UK
Many gene mutations and chromosomal aberrations have been
identified that are thought to be involved in malignant breast
cancer. However, it is likely that many other genes, not yet identi-
fied, also have a role. Comparative genomic hybridization (CGH)
allows the analysis of copy number changes across the entire
tumour genome in a single hybridization. CGH is based on the
competitive hybridization of two differentially labelled DNA
samples to normal metaphase spreads. Tumour DNA is labelled
with a green fluorochrome and normal reference DNA is labelled
with a red fluorochrome. Image analysis compares the intensity of
the green to red staining and calculates the ratio, thus allowing
areas of amplification or deletion to be identified throughout the
entire genome.
In this study, 15 consecutive breast tumours were analysed. All
were staged according to standard TNM classification. Reference
DNA was extracted from the patients' lymphocytes to provide a
more sensitive reaction than using commercially available normal
DNA, this is because heterochromatic regions are more compa-
rable. To distinguish between somatic and germline mutations the
tumour specimens were also compared with standard reference
DNA (Vysis).
A wide variety of copy number changes were identified.
Recurrent regions ofamplification involved lq (12 of 15), 3q (9 of
15), 8q (8 of 15), 12p (8 of 15) and 20p (9 of 15). The average
number of amplifications per tumour was 12.7 + 6.4, involving
8.5 ± 3.3 chromosomes in each tumour. Recurrent regions of dele-
tion involved 17p (7 of 15) and 15p (7 of 15). The average number
of deletions per chromosome was 10 ± 4.2, involving 5.1 ± 3.8
chromosomes in each tumour. The greatest number of aberrations
(30) was found in a T4 tumour. The sites of most ofthe aberrations
identified were distinct from those of currently known cancer
genes, indicating that a number of other chromosomal loci are
involved in the progression of malignant breast cancer. Further
studies will be required to identify the genes and the role(s) they
play in breast carcinogenesis.
Evaluation of EGF receptor tyrosine
kinase inhibitors identifies a potential
selective inhibitor of MAP kinase
J Edwards', CS Gibb2, D Robins2 andJMS Bartlett'
'University Department of Surgery, Level II, Queen Elizabeth Building,
Glasgow Royal Infirmary, Glasgow; 2Department of Chemistry, University of
Glasgow, Glasgow, UK
Epidermal growth factor (EGF) pathways have been shown to
stimulate cellular proliferation in ovarian cancer cells, and EGF
receptor expression is associated with poor prognosis in ovarian
cancer patients. Therefore, we have investigated the possibility of
using EGF-specific tyrosine kinase inhibitors as a novel treatment
of ovarian cancer. We have screened a series of tyrosine kinase
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inhibitors, as potential therapeutic agents for the treatment of
ovarian cancer. The potency of these drugs against EGF-stimu-
lated PEO1 ovarian carcinoma cell growth was evaluated using an
MTT assay (Table 1).
Table 1 MTT results for EGF-mediated proliferation in PEO1 ovarian
carcinoma cells
Drug IC50 Drug IC50
CSG2 1.79 CSG6 27.82
CSG7 16.68 CSG15 39.66
CSG3 18.77 CSG13 44.15
CSG9 18.77 CSG17 56.51
CSG10 18.77 CSG14 77.43
CSG16 26.23 CSG19 98.05
IC50, dose causing 50% inhibition of growth factor-mediated proliferation over
6 days.
Of the 12 compounds evaluated using this system, CSG 2 was
found to be the most potent inhibitor of EGF-stimulated cell
growth. Further evaluation of CSG 2 and CSG 7 by Western blot-
ting confirmed the ability of these agents to inhibit phosphoryla-
tion ofthe EGF receptor and its downstream targets. Activation of
the EGF receptor kinase was inhibited by both CSG 2 and CSG 7
in a cell-free system where EGF receptor protein was extracted
from A43 1 cells. EGF-stimulated MAP kinase activity was
reversed when PEOl cells were treated with CSG 2 or CSG 7.
However, CSG 2 and CSG 7 were more active against activated
MAP kinase (IC 50 value of 2 JIM and 18 ,UM respectively) in a cell-
free system than the EGF receptor (ICQ1 value 26 ,UM and 59 JM
respectively). This suggests that a principal site of action of both
these drugs when inhibiting EGF-stimulated ovarian cell growth is
at MAP kinase.
Chromosome abberations in TCC
predictive of disease outcome are
independent events not associated with
polyploidy
JMS Bartlett1, AD Watters1, L Adie1, JJ Going2 and
KM Grigor3
University Department 'of Surgery and 2Pathology, GRI, Glasgow;
3University Department of Pathology, Edinburgh, UK
Transitional cell carcinoma of the bladder (TCC) is the fourth
commonest carcinoma in men, and frequent multiple recurrences
(45% within 2 years) with risk of progression (10-20%) mandate
extensive follow-up. Molecular markers of disease outcome
should provide valuable diagnostic information allowing early
treatment of patients at high risk of recurrence. We have previ-
ously reported that monosomy of chromosome 9 is predictive of
recurrence, and polysomy of chromosomes 7 and 17 predicts
progression in TCC. The current study was designed to establish
whether such events were independent oftumour cell polyploidy.
Quantitative fluorescence in situ hybridization using alpha
satellites was performed to detect chromosomes 10 and 11 in
archival material from 12 patients with known status of chromo-
some 9, 7 and 17. Monosomy or polysomy was defined as a mean
signal nuclear ratio (MSNR) outwith the normal range (1.5-1.8).
Patient Chrom 9 Chrom 10 Chrom 11 Chrom 17 Chrom 7
NR1 Monosomy Disomy Disomy Disomy Disomy
NR2 Disomy Disomy Disomy Disomy Disomy
NR3 Disomy Disomy Disomy Disomy Disomy
NR4 Disomy Disomy Disomy Disomy Disomy
RNP1 Monosomy Disomy Polysomy Polysomy Polysomy
RNP2 Monosomy Monosomy Disomy Disomy Disomy
RNP3 Disomy Disomy N.D. Disomy Disomy
RNP4 Disomy Disomy Disomy Polysomy Polysomy
RP1 Monosomy Disomy Disomy Polysomy Polysomy
RP2 Monosomy Disomy Disomy Disomy Disomy
RP3 Disomy Disomy Disomy Disomy Disomy
RP4 Disomy ND ND Polysomy Polysomy
ND, not done; NR, non-recurrer; RNP, recurrer non-progressor; RP, recurrer
progressor. Disomy, 2n; monosomy, 1 n; polysomy, 3+N.
In conclusion, loss ofchromosome 10 occurs infrequently (9%), as
does polysomy for chromosome 11 (10%). Polysomy of chromo-
somes 7 and 17 occurs independently of either monosomy 9 or 10
or, more significantly, polysomy 10 or 11. This finding would indi-
cate that polysomy 7 and 17 identifies a chromosome-specific
event unrelated to tumour polyploidy or monosomy 9.
Liver resection for colorectal metastases:
results and prognostic factors
D Al-Musawi, P Hansen, H Tanaka, A Isla and NA Habib
Department of Surgery, ICSM, Hammersmith Hospital, Du Cane Road,
London W12 ONN, UK
From January 1990 until February 1997, 41 patients (12 male, 29
female, mean age 59 years, range 31-79 years) underwent 53
hepatic resections for liver metastases of colorectal primary
tumours. Five, four and three patients underwent two, three and
four resections, respectively, for recurrent liver metastases. The
primary tumour was located in the rectum in 20 patients and the
colon in the others. Liver metastases included 18 synchronous
with the primary tumour, 23 metachronous, 23 unilobar and 18
bilobar. Major hepatic resection was performed in 34 (83%)
patients and minor resection, which included segmentectomies
and non-anatomical resection, in seven (17%) patients. Total
vascular exclusion was used in 33 patients (mean ischaemic time
32 min) and the Pringle manoeuvre in eight patients (mean
ischaemic time 39 min). There were 25 (61%) patients with
'potentially curative' initial liver resection and 16 (39%) patients
with minimal macroscopic (n = 12) or microscopic (n = 4) residual
disease. The mean (s.d.) operative blood transfusion was 2.1 (1.8)
units packed red cells (range 0-8 units); 11 patients did not receive
blood transfusion. Operative mortality was zero, but there was one
in-hospital death 2 months after surgery (mortality rate 2.4%);
non-fatal complications developed in 11 (27%) patients. Overall 2-
year and 5-year survival rates after liver resection were 55% and
40%. Using Cox regression and log-rank tests: multiplicity of
tumours, bilobar involvement, major or minor liver resection,
synchronous or metachronous metastasis, sites of primary tumour,
Dukes' staging and histological grading had no significant effect
on survival. There were significant relationships with survival for
size of tumour (P = 0.0203), carcinoembryonic antigen (P = 0.01)
and preoperative alkaline phosphatase (P = 0.04). Surgical resec-
tion is still the best available option for fit patients with resectable
colorectal liver metastases.
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Genetic analysis of head and neck
squamous cell carcinoma and
surrounding uninvolved mucosa by
comparative genomic hybridization
JNEAshman', J Greenman2, SR Eli' and ND Stafford'
'Department of Otolaryngology and Head and Neck Surgery, Hull Royal
Infirmary, Anlaby Road, Hull; 2Department of Surgery, Academic Surgical
Unit, University of Hull, Cottingham Road, Hull HU6 7RX, UK
Squamous cell carcinoma of the head and neck has a high inci-
dence of development of synchronous and metachronus primary
tumours, relative to other solid tumours. Much interest has focused
on the mucosa adjacent to primary tumours and led to the theory of
'field cancerization', in which prolonged exposure to carcinogenic
insult leads to alteration of local mucosa.
Comparative genomic hybridization was used to investigate
whether gene copy number aberrations could be detected in histo-
logically normal mucosa from patients with squamous cell carci-
noma. Samples were collected from 13 patients (nine laryngeal,
three tonsil and one tongue carcinoma). Three tissue samples per
patient were analysed: tumour, tumour margin (1 cm away) and
distant 'normal' mucosa (5 cm from tumour). Genomic DNA
extracted from each sample was nick labelled in the presence
of fluorescein- 12-dUTP and competitively hybridized against
Spectrum-Red-labelled reference DNA. Analysis was performed
on a Vysis Quips workstation to produce a copy number profile for
each sample.
Copy number changes were not seen in genomic DNA extracted
from any of the samples taken from 1 cm and 5 cm distant to the
tumour. Common copy number changes were, however, seen in
the tumour samples: deletions, 3p (9 of 13), 1 lq (6 of 13), 5q (5 of
13), 9p (5 of 13), 18q (5 of 13), 13q (5 of 13), 4q (4 of 13), 8p (4 of
13); amplifications, 3q (7 of 13), 8q (6 of 13), 5p (4 of 13), 1lq (3
of 13). Simultaneous complete deletion of 3p and amplification of
3q occurred in 54% of tumours, suggesting the formation ofthe 3q
isochromosome. Several loci ofinterest were identified containing
known or putative oncogenes and tumour-suppressor genes
involved in head and neck cancer progression. The region
3p24-p25.1 has previously been suggested as the site of a tumour-
suppressor gene, and this was seen to be deleted in 70% of
tumours. Amplification of the I I q 13 locus occurred in 23% of the
tumours. This region harbours the PRAD-1 gene coding for the
cyclin DI cell cycle-regulatory protein.
This study shows no evidence of copy number changes in the
'normal' mucosa ofhead and neck cancer patients, suggesting either
that factors responsible for the putative 'field cancerization' are
acting at a sub-chromosomal level or that the altered cells account
for only a small proportion ofthe mucosa surrounding the tumour.
Cytochrome P450 in human brain
tumours
MCE McFadyen', WTMelvi& and GI Murray'
'Department of Pathology, 2Department of Molecular and Cell Biology,
University of Aberdeen, Foresterhill, Aberdeen AB25 2ZD, UK
The cytochromes P450 (P450) are a large group ofconstitutive and
inducible oxidative enzymes with a major role in the metabolism
of xenobiotics, including carcinogens and anti-cancer drugs. This
family of enzymes are thus involved in tumour development and
the response of established tumours to anti-cancer drugs. In this
study, we have investigated the presence and cellular localization
of individual families of P450 in normal human brain and primary
brain tumours. Sections of formalin-fixed wax-embedded normal
and tumour brain were used and the immunoreactivity of indi-
vidual P450s was identified using light microscopic immunohisto-
chemistry. In normal brain, immunoreactivity was observed for
CYPIA, CYP2C, CYP2E1 and CYP3A, while there was no
immunoreactivity for CYPlB1. Immunoreactivity in normal brain
was mainly localized to neuronal cell bodies. All the tumours
studied were astrocytomas, and CYPIA was present in 96% of
tumours, while CYPlBl was present in 87% of tumours. There
was no significant immunoreactivity for CYP2C and CYP2E1.
CYP3A immunoreactivity was identified in 43% oftumours. In all
cases, positive immunoreactivity for each P450 was identified in
tumour cells and, generally, in positively staining cells, the
immunoreactivity was strong. The presence ofindividual forms of
the CYP1 and CYP3A families in brain tumours provides further
evidence for the expression of specific forms ofP450 in malignant
tumours. Individual forms of P450 in brain tumours could be
important therapeutically for the development ofanti-cancer drugs
that are activated by those forms of P450.
This research was supported by grants from The Association for
International Cancer Research and Tenovus-Scotland.
Cytokine expression during ADCC of
colorectal tumour cells using murine and
humanized antibodies
KM Gaskell, J Greenman, JAshman, RJ O'Hara and
JRTMonson
Academic Surgical Unit, University of Hull, Hull HU6 7RX, UK
Antibody-dependent cell-mediated cytotoxicity (ADCC) is a reac-
tion in which leucocytes bearing Fc receptors recognize and lyse
target cells, such as tumour cells, via specific antibodies. Little is
known about the interaction between effector cells, antibodies and
tumour cells, or about the mechanism of subsequent tumour cell
lysis. In vitro and in vivo studies have consistently shown that
humanized antibodies are vastly superior to murine antibodies in
mediating ADCC. Therefore, expression of a panel of cytokines
during an in vitro ADCC assay using both murine and humanized
antibodies was investigated, to determine whether different types of
antibody induce different cytokine mRNA expression. ADCC
assays (18 h) were performed using the colorectal cell line HT-29 as
targets and peripheral blood mononuclear cells from seven
colorectal cancer patients and four normal donors as effector cells.
The murine antibodies m17-1A and 323-A3 were tested, along with
their respective humanized counterparts c17-1A and 3622W94. The
irrelevant antibodies DB7/12 and 7E3 were also used as murine and
humanized controls. Cytotoxicity was assessed using a colorimetric
assay measuring lactate dehydrogenase (LDH) release from dead or
damaged cells. Expression ofvarious cytokines was assessed by RT-
PCR using intron spanning oligonucleotide primers. The identity of
PCR products was confirmed using restriction enzyme digestion.
The optimal antibody concentration and effector-target ratio
were determined to be 1 ,ug ml- and 50:1 respectively. Effector
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cells from patients with colorectal cancer mediated similar levels
of ADCC to those from normal donors. In both the patient and the
control groups, the humanized antibodies 3622W94 and c17-1A
proved vastly superior in mediating ADCC to their murine
counterparts, displaying levels of tumour cell lysis in the range
of 80-90% and 40-50% respectively.
TNF-oc,TGF-P, IL-loc, IL-I , IL-6, IL-8, IL-10, IL-12 (p40) and
IL-15 were consistently detected in ADCC conditions containing
effector cells alone, both in the patient and in the control group. No
additional cytokines were observed when effector cells were incu-
bated with target cells and/or antibodies. Other control conditions
using effector cells and antibody, or target cells and antibody,
produced the same cytokine profiles as effector cells alone and
target cells alone respectively. Varying the antibody concentration
between 0.01 ,ug ml-'and 100 ,ug ml-'had no effect on the cytokine
profiles. These findings indicate that, for the panel of cytokines
tested, no cytokine mRNA is induced or 'switched off' during an
18-h ADCC reaction with either murine or humanized antibodies.
However, there may be changes in the mRNA levels, but quantita-
tive PCR analysis is required to investigate this.
Characterization of a p53 oligomerization
domain mutation isolated from a
Li-Fraumeni-like family member
ME Lomax', DM Bames2, SMPicksley3 andRS Camplejohn'
'Richard Dimbleby Department of Cancer Research, UMDS, St Thomas'
Hospital, London SE1 7EH; 21CRF Clinical Oncology Unit, Guy's Hospital,
London SE1 9RT; 3CRC Cell Transformation Group, Department of
Biochemistry, University of Dundee, Dundee DD1 4HN, UK
The tumour-suppressor gene p53 has been associated with the
inherited cancer prone syndromes, Li-Fraumeni syndrome (LFS)
and Li-Fraumeni-like syndrome (LFL). Recently Lomax et al
(Oncogene 1997, 14: 1869) described a point mutation in the
oligomerization domain of p53 (codon 337 R to C) in a LFL
family member and Varley et al (Oncogene 1996, 12: 2437)
discovered a point mutation at codon 344 L to P, also in the
oligomerization domain ofp53, in a LFS family. Until recently, the
role of point mutations in the oligomerization domain ofp53 was
disputed.
The two described mutations have been generated in both E.
coli and mammalian expression plasmids and the resulting
proteins assessed for their abilities to perform certain functions of
wild-type p53 protein. The oligomerization domain mutations
have been compared with both wild-type p53 and with a core
DNA binding domain mutation, codon 248 R to Q, which is a
frequent mutation in human cancer.
The results obtained thus far suggest that the 344 L to P mutation
is defective for DNA binding and induces apoptosis at levels about
20% of wild-type p53 and transactivates luciferase from a
luciferase-bax reporter at about 6% of wild-type p53, in the p53-
null cell line Saos-2. These results are very similar to those
obtained with the 248 R to Q mutation. The 337 R to C mutation,
however, does bind to DNA but is not fully functional at inducing
apoptosis and transactivating luciferase from a luciferase-bax
reporter, giving only 50-60% of wild-type activity. In addition,
work on the inhibition ofgrowth ofSaos-2 cells by the various p53
mutants has also been carried out and a similar pattern ofresults has
been found, in which wild-type p53 resulted in a very small number
offoci, 344 L to P and 248 R to Q resulted in a large number offoci
and 337 R to C resulted in an intermediary number of foci.
These results indicate that point mutations in the oligomeriza-
tion domain of p53 could play a role in tumorigenesis and also
demonstrate the value of LFS and LFL families as models for the
further understanding ofthe biological and biochemical properties
ofthe p53 tumour-suppressor gene.
Genetic alterations of N-acetyl
transferase in transitional cell carcinoma
of the bladder
AD Watters', MWStacey2, JJ Going3, KM Grigor4,
TG Cooke1, E Sirrs andJMS Bartlett1
'University Department of Surgery, GRI, Glasgow; 2University Department of
Pharmacology, Oxford; 3University Department of Pathology, GRI, Glasgow;
4University Department of Pathology, Edinburgh
Transitional cell carcinoma of the bladder (TCC) is the fourth
commonest carcinoma in UK men and strong links with exposure
to chemical carcinogens have been demonstrated [1,2]. N-acetyl
transferase 1 and 2 are known to metabolize these compounds. The
genes (NAT] and 2) are located at 8p22 [3], and this region is
frequently deleted in high-stage and -grade bladder tumours
(detrusor muscle invasive) [4].
To further investigate a potential role for NAT2 in TCC, a cohort
of patients (n = 19, no. of tumours 40) with previously diagnosed
TCC and full clinical follow-up (mean 5 years) was studied. Dual-
colour quantitative fluorescence in situ hybridization to detect
NAT2 and chromosome 8 was applied to archival material.
Three clear patterns of mutation were observed. Forty per cent
(four of ten) of patients with non-invasive carcinoma showed a
loss ofNAT2, one of whom also had polysomy 8. Eighty-nine per
cent (eight of nine) of patients with invasive carcinoma had aber-
rations of NAT2. Of these, 50% (four of eight) showed a loss of
NAT2, three of whom also had polysomy 8. The remaining four
patients demonstrated multiple copies of NAT2, possibly indi-
cating gene amplification, and polysomy 8.
In conclusion, a large proportion of patients in this study had
abnormalities of chromosome and gene copy number. NAT2 was
deleted in some cases while others had apparent increases in copy
number. Selective retention of NAT2 in some tumours has been
reported [5], and the range of gene abnormalities may emphasize
the complex metabolic role ofNAT2 in carcinogenesis.
REFERENCES
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Oral eicosapentaenoic acid reduces
experimental human pancreatic tumour
growth in SCID mice
MD Barber, KCH Fearon andJA Ross
University Department of Surgery, Royal Infirmary of Edinburgh, Edinburgh
EH3 9YW, UK
We have recently shown that eicosapentaenoic acid (EPA), an n-3
fatty acid derived from fish oil, will attenuate cachexia in patients
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with advanced pancreatic cancer at a dose of 6 g daily with
minimal side-effects (Barber et al, 1997, Prostaglanid Leukot
Essent FRittm Acids 57: 204). Others have suggested that EPA will
slow experimental tumour growth in mice but most have used
mixed fish oil preparations, administered the agent by non-physio-
logical routes or given substantially more fat than is present in the
normal diet. Many groups also began feeding experimental diets
before tumour implantation. This study aimed to assess the effect
ofdietary high-purity EPA upon the growth of a human pancreatic
cancer cell line in immunocompromised mice.
Fragments of tumour derived from the MIAPaCa-2 human
pancreatic cancer cell line were transplanted subcutaneously on
the left flank of 5- to 6-week-old female SCID (severe combined
immunodeficiency) mice with Home Office approval. From the
day after tumour implantation, mice were fed a sterile purified fat-
free diet, based on American Institute of Nutrition guidelines, to
which was added oil to make up 5% of the final diet weight using
either corn oil or 95% pure EPA as free acid (4%, plus 1% corn
oil). Mice were killed before the tumour burden became excessive
at around 3 weeks. Groups of 12 mice on each diet were used
concurrently on each occasion. Matched groups of animals
without tumours were also studied.
Mice fed the diet enriched with EPA had significantly smaller
tumours than control animals [median 2810 mm3 (interquartile
range 2050-3790) vs 4960 mm3 (3210-6320), P = 0.023,
Mann-Whitney U-test]. Liver and spleens of tumour-bearing
animals were substantially heavier than non-tumour-bearing
controls (P < 0.001). Histological examination revealed multiple
metastases in these organs in tumour-bearing animals. Liver and
spleens of tumour-bearing animals were significantly lighter in
those fed EPA compared with those fed corn oil (P < 0.001),
suggesting a reduced metastatic burden.
Mice fed EPA ate significantly less food than controls
(2.25 g day-' vs 3.05 g day-', P = 0.021). As diet restriction has
been suggested to inhibit carcinogenesis, the experiment was
repeated supplying matched amounts offood. Again tumours were
significantly smaller in EPA-fed mice [3080 mm3] (1800-3990) vs
4800 mm3 (3060-6400), P = 0.027] and liver and spleens were
significantly lighter with EPA (P < 0.02), suggesting that the
tumour growth reduction was due to EPA and not diet restriction.
We conclude that 6-8 g kg-' EPA within the diet will slow the
growth of a human experimental tumour and reduce metastatic
spread in a mouse model. The potential ofEPA as a non-toxic anti-
cancer agent deserves further study in human neoplastic disease.
Infectivity and selective replication of an
El B deficient adenovirus in mouse cell
lines
I Ganly1, R Brown' andA Balmai&2
'CRC Department of Medical Oncology, CRC Beatson Laboratories,
Glasgow G61 1BD, UK; 2Onyx Pharmaceuticals, 3031 Research Dr. Bldg. A,
Richmond, California 94806, USA
Selectively replicating adenoviruses may have a role to play in
cancer therapy. At present, there is no immunocompetent mouse
model to test replicating adenoviruses as previous work suggests
that both the infectivity and the productive replication of adeno-
viruses in mouse cells is poor. The aim ofthis study was to develop
an immunocompetent mouse model to test the activity of selec-
tively replicating adenoviruses.
Infectivity of mouse cells from a wide range oftissue types was
determined using a non-replicating EIA,EIB-deleted adenovirus
with a lacZ reporter construct. Cell monolayers were infected at 0,
1, 10 and 100 p.f.u. cell-' and the percentage ofbeta galactosidase-
positive cells measured 24 h post infection. Viral replication and
cytolysis after wild-type adenoviral type 2 infection was deter-
mined by cytopathic effect assays and hexon protein staining at an
infection titre of 10 p.f.u. cell-'. Quantitation of replication was
measured at 4 h and 72 h post infection by plaque-forming assays
on 293 cell monolayers. The selectivity of a p53-dependent ElB-
deleted adenovirus, Onyx-015, was tested on mouse epidermal
cells ofknown p53 status using hexon protein staining and plaque-
forming assays.
Contrary to previous work, infectivity of mouse cells of
different tissue types was found to be high and was often greater
than human cells at the same infection titre. The infectivity of 3T3
fibroblasts was, however, very low. Wild-type adenovirus Ad2
replicated in and produced a rising titre in specific mouse cell
types, in particular mouse epidermal cells. However, the viral yield
was 10-50 times less than in human cells. Onyx-015 showed
selective replication in mouse epidermal cells that lacked func-
tional p53.
Adenoviral infectivity of mouse cells is high and productive
infections will occur in specific tissue types notably epidermal
cells. Using Onyx-015 virus, replication is shown to be selective for
p53 mutant cells. These studies will enable us to test the activity of
oncolytic adenoviruses in vivo in immunocompetent mice.
Virus-directed enzyme prodrug therapy
using retrovirally delivered E. coli
nitroreductase and CB1954
IA McNeish', MG Gilligan1 NK Green2, SM Roberts1,
DJ Kerr', F Friedlos3, CJ Springerand PFSearle'
'CRC Institute for Cancer Studies and 2Department of Surgery, University of
Birmingham, B15 2TA; 31nstitute for Cancer Research, Sutton, SMG 5NG, UK
The E. coli enzyme nitroreductase (NTR) converts the weak,
monofunctional alkylating agent CB1954 (5-(aziridin- -yl)-2,4-
dinitrobenzamide) into a highly active bifunctional metabolite that
is toxic to both cycling and non-cycling cells. Using high-density
cell mixing experiments with a SKOV3 clone expressing high-
level NTR, we have previously shown that a significant bystander
effect exists in vitro for the NTR/CB 1954 combination: when only
5% of cells express NTR, the LD50 is reduced tenfold compared
with parental cells and, if 30% of cells in the mixture express
NTR, the population acts as if 100% are NTR positive.
We have used the packaging cell lines gp+env AM12 and FLY
RD18 to produce the recombinant retrovirus LNC-ntr at titres of
1-5 x 105 c.f.u ml-'. Using this virus, we have transduced the
ovarian carcinoma lines SKOV3, IGROVI and cisplatin-resistant
A2780 CP, as well as early-passage cells derived from the ascites
of patients with advanced ovarian carcinoma. Single transduction
gives an MOI of approximately I and a transduction efficiency of
around 25%, and produces a tenfold increase in sensitivity to
CB1954 of bulk unselected cells without reliance on antibiotic
selection or cell cloning procedures.
One of the main disadvantages of retroviruses as vectors for
gene therapy is their relatively low titre. Using low-speed (6000g)
overnight centrifugation, we have been able to increase retroviral
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titre 100-fold to approximately 5 x 107 c.f.u. ml-'. Using this
concentrated virus, we have transduced SKOV3 and A2780 cells
with transduction efficiencies approaching 100% to produce a
400-fold increase in bulk unselected cell sensitivity to CB1954.
To improve the ability to visualize NTR expression in vitro and
in vivo, we have tagged NTR with a novel 30mer derived from the
Human Papilloma Virus Type 1 E4 gene. We have shown that the
tagged NTR is still functional in vitro and can be detected by anti-
HPV E4 monoclonal antibodies.
We have grown subcutaneous tumours in nude Balb C mice
using SKOV3 cells and a SKOV3 clone expressing high-level
NTR. Two intraperitoneal injections of CB1954 (50 mg kg-')
given I week apart produce marked growth delay of the NTR
tumours, although not complete cure, and a corresponding
increase in survival in these animals.
HPMA copolymer platinates as novel
anti-cancer agents
E Gianasi1, E Evagorou', RG Buckley1, S Knellerl,
N Malik', G Wilson2 and R Duncan1
'Centre for Polymer Therapeutics, School of Pharmacy, London WC1 N 1AX;
2Access Pharmaceuticals, Dallas, USA
Since its discovery cisplatin has had a major impact on cancer
chemotherapy, but new platinum analogues have shown minimal
improvement compared with cisplatin. Preparation of polymer
platinates is an attractive strategy to reduce systemic toxicity, to
localize more drug in the tumour via the enhanced permeability
and retention (EPR) effect and to overcome resistance. The
concept of polymeric anti-cancer agents (Duncan et al, 1996, STP
Pha,-na Sci 6: 237) has been established clinically in the form of
the N-(2-hydroxypropyl) methacrylamide (HPMA) copolymer
doxorubicin (PKI) (Vasey et al, 1996, Ainn Onicol 7: 97). The
design ofeffective polymer platinates is challenging. It is essential
to select a biocompatible carrier and to release a biologically
active platinate in the tumour, and that the platinum is tightly
bound to the polymer during transport in the circulation and during
elimination of the conjugate via the kidney.
Four classes of polymer have been investigated as polymeric
platinates: natural polymers, poly(amidoamine)s, PAMAM
dendrimers and HPMA copolymers, with the last being selected
for development of a clinical candidate. HPMA conjugates
(M,
- 30 000; Pt content 5-10 wt%) were prepared containing
pendant peptidyl side-chains terminating in ligands capable of
coordinating platinum. Active Pt species are released from the
conjuate either by hydrolysis or by enzymatic degradation of the
peptidyl side-chains. Release rates have been tailored by conjugate
design. In vivo evaluation against a panel of tumours has shown
that several conjugates display equi-effective anti-tumour activity
compared with cisplatin after i.p. administration to treat an i.p.
tumour, thus confirming their ability to liberate active Pt species in
vivo. However, when administered i.v. to treat s.c. B16F1O
melanoma, the polymeric conjugates showed a dramatic increase
in activity. Pharmacokinetic studies have shown that Pt conjuga-
tion leads to an increase in B16F10 AUC of 63-fold compared
with that achieved at the MTD for cisplatin in this model. This is
consistent with polymeric tumour capture by the EPR effect. The
polymeric platinates were less toxic than cisplatin (two- to 15-
fold) and warrant clinical evaluation.
Inhibition of angiogenic factor- and
tumour-induced angiogenesis by gamma
linolenic acid
J Cai, WG Jiang and RE Mansel
University Department of Surgery, University of Wales College of Medicine,
Cardiff, UK
Angiogenesis is an essential event in the formation of metastasis.
We examined the effect of gamma linolenic acid (GLA), an anti-
cancer polyunsaturated fatty acid, on the angiogenesis and motility
of vascular endothelial cells.
A rat aortic ring assay was used to determine angiogenesis [spon-
taneous, angiogenic factor or tumour cell (MDA MB 231 breast
cancer) induced]. The motility of a human vascular endothelial cell
line, ECV304, was assessed using a cytocarrier assay and colloidal
gold phagokinetic assay. GLA was tested over a range ofconcentra-
tions (1-50 ltM). In a three-dimensional matrix, aortic rings gener-
ated new vessels after 3 days, reaching a maximum number after
14 days. The angiogenesis was stimulated by both angiogenic factor
(scatter factor) (number of new vessels ± s.e.m. was 15.0 ± 3.2) and
breast cancer cells (33.6 ± 3.5), compared with control (11.0 ± 2.4).
Inclusion of GLA in this assay resulted in a concentration-depen-
dent inhibition of angiogenesis in non-stimulated (0.4 ± 0.3), angio-
genic factor-stimulated (2.0 ± 0.8) and tumour cell-stimulated (12.7
4.3) cultures. In the motility assay, inclusion of GLA reduced the
migration of the endothelial cells (ECV304) as shown by a reduc-
tion in phagokinetic clearance of colloidal gold particles. In the
cytocarrier motility assay, a significant reduction of the motility of
ECV304 by gamma-linolenic acid was also seen (motility index
being 53.3 ± 4.5 with GLA vs 85.0 ± 11.7 in control, P = 0.011 by
Student's t-test).
We conclude that gamma linolenic acid, a ni-6 series essential
fatty acid, inhibits angiogenic factor- and tumour cell-induced
angiogenesis in vitro. This inhibitory effect is partly due to its
inhibition of the motility of vascular endothelial cells.
Evidence for an immunomodulatory role
for ox-MSH in cutaneous and ocular
melanoma
JW Haycock', KDorset', M Wagner', IR Rennie2
and S MacNeil1
Departments of 'Medicine and 20phthalmology and Orthoptics, Clinical
Sciences Centre, Northern General Hospital, Sheffield S5 7AU, UK
Normal human melanocytes may require ot-MSH to resist the
action of ultraviolet (UV) light, which has the potential to
initiate cellular damage and local inflammation. Recently,
we have also found oc-MSH to oppose the ability of TNF-oc to
up-regulate ICAM-1, leading us to speculate that oc-MSH may
have a role in down-regulating particular cell-surface molecules
necessary for immune system recognition and targeting (e.g.
ICAM-I), which are normally inducible via inflammatory
cytokines (e.g. TNF-oc). We investigated this concept by consid-
ering how ct-MSH might oppose the ability of TNF-ux to activate
relevant transcription factors in human cutaneous and ocular
melanoma cells.
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NF-KB is a transcription factor responsible for expression of
several genes, many of which are necessary for a successful
response to cellular stress. It is known to be inducible by a number
of cellular agents (e.g. cytokines) and also environmental factors
(UV light). We studied the functional DNA binding activity of
NF-KB using electrophoretic mobility shift analysis in A375-SM
human cutaneous melanoma cells. Cells showed little constitutive
expression ofthe p50:p65 heterodimer NF-KB complex. However,
incubation with TNF-oc (200 U ml-') for 2 h gave a maximum level
of up-regulated activity in this particular complex alone.
Importantly, co-incubation of the cells with TNF-tx (200 U ml')
and ox-MSH (10-"'m - 10- M) gave a significant decrease in the
level of the TNF-oc-induced NF-KB activity (by approximately
50%, over 2 h). [ca-MSH alone (10-l" M - 10-1 M) had no effect on
functional binding activity.] In addition, the co-incubation of cells
with TNF-ox (200 U ml-') and IBMX (1 mM) for 2 h also showed a
50% decrease in the level of TNF-oc inducible activity, suggesting
that the action of cx-MSH can be mimicked by a receptor-indepen-
dent elevation in cAMP. In contrast, analysis of an ocular
melanoma cell line revealed a high constitutive activity of NF-KB
that was unresponsive to the action of TNF-ux or ux-MSH.
However, an alternative Rel family complex (possibly p50) was
upregulated by TNF-oc (200 U ml-', 1 h), and this increase was
reduced by co-incubation of the cells with TNF-ux and ct-MSH
(10-9 M). These results support the hypothesis that oc-MSH may be
acting as an immunomodulatory peptide in suppressing the
response of melanoma cells to cytokines, which might otherwise
bring these cells to the attention of the immune system.
HGF/SF induces disruption of
intercellular tumour cell adhesion:
involvement of 3-catenin
S Hiscox and WG Jiang
Department of Surgery, University of Wales College of Medicine, Cardiff,
S. Wales, CF4 4XN, UK
Metastasis is the single, most important factor that determines
cancer patient prognosis. Early stages of epithelial tumour cell
metastatic spread involve loss of E-cadherin-mediated cell-cell
adhesion within the primary tumour mass. Hepatocyte growth
factor/scatter factor (HGF/SF) greatly stimulates the metastatic
potential of tumour cells and promotes the 'scattering' of tightly
packed tumour cell colonies. The aims of this study were thus to
investigate the effects of HGF/SF on E-cadherin (E-cad) and its
associated catenin molecules (ot, 3 and y) in epithelial tumour cells.
The effects of HGF/SF on two colorectal carcinoma cell lines,
HT115 (E-cad-) and HRT18 (E-cad+), were monitored by time-
lapse video microscopy. The expression and tyrosine phosphoryla-
tion ofE-cadherin and catenins in response to HGF/SF stimulation
were determined by immunocytochemistry and Western blotting/
immunoprecipitation respectively.
HRT18 cells were observed to form very tight colonies in
culture, while HT1 15 cells formed colonies in which cells were
loosely packed. HGF/SF caused significant scattering of HT115
cell colonies and promoted the disruption of intercellular cell-cell
adhesions in HRT18 cell colonies. This resulted in the partial scat-
tering ofthese colonies. HGF/SF had no effect on the overall level
of E-cad or associated catenin molecules in HRT18 cells, but did
enhance the tyrosine phosphorylation status of f-catenin in these
cells, an effect that was observed as early as 30 min after HGF/SF
treatment. The amount of 3-catenin co-precipitating with E-cad
was reduced after HGF/SF treatment.
We conclude that HGF/SF-induced phosphorylation of,B-catenin
results in a reduction of association of this molecule with E-
cadherin and thus a loss of function of the E-cadherin adhesion
complex. The association of catenin molecules with cell-surface
cadherin is an essential requirement forcadherin-mediated cell-cell
adhesion. These data therefore implicate HGF/SF as a possible
regulator of early events in the metastatic progression of tumours
by promoting loss of E-cadherin-mediated cell-cell adhesion.
Inhibition of colon tumour promoter-
induced COX2 mRNA induction by
curcumin correlates with inhibition of
NFkB DNA-binding and transactivation
KA Holloway', RJL Munks2, M-A Peer' and SM Plummer'
'Centre for Mechanisms of Human Toxicity and 2MRC Toxicology Unit,
University of Leicester, Leicester LE1 9HN, UK
Prostaglandins may play an important role in colon carcino-
genesis. Non-steroidal anti-inflammatory agents (NSAIDs), which
inhibit their production by prostaglandin H synthase (PGHS), may
reduce colon cancer risk by 50% and can inhibit development of
colon tumours in animal models of this disease. The COX2 gene,
an inducible form of PGHS, is overexpressed in human colon
tumours and is a potential target for the chemopreventive effects of
these agents. In this study, we have investigated the effects of
endogenous colon tumour promoters, fecapentaene-12 (fec-12)
and TNF-oc on COX2 gene expression in the human colon epithe-
lial cell line HCEC and human colon carcinoma cell line SW480.
Furthermore, we have investigated the mechanism of action ofthe
colon cancer chemopreventive agent curcumin (CUR). Exposure
of HCEC cells to TNF-ot (0.1-10 ng ml-') or fec-12 (10-40 ,tM)
for 2 h caused a dose-dependent two- to sevenfold induction of
COX2 mRNA levels, measured by RT-PCR. The TNF-oc and fec-
12 induction of COX2 mRNA peaked at 3 h and returned to
control levels by 24 h. As there is evidence that COX2 gene induc-
tion is controlled in part by the transcription factor NFkB, we also
investigated the effects of these agents on NFkB-DNA binding to
'consensus' or 'COX2-promoter' NFkB oligonucleotides by
EMSA. TNF-ox (0.1 or 1Ong ml-') and fec-12 (20 ltM) caused a
four- to five- and fourfold induction of NFkB DNA binding to
these oligos respectively. Treatment of SW480 cells with TNF-oc
caused a threefold induction of luciferase expression in transfec-
tion studies with a luciferase reporter construct containing six
NFkB binding sites (pNFkB). Pretreatment of cells with CUR
(10-40,M) for 1 h before TNF-oc or fec-12 exposure caused a
dose-dependent 20-90% inhibition of COX2 mRNA induction.
CUR caused a dose-dependent 30-90% inhibition of NFkB DNA-
binding activity in EMSA assays and inhibited the activation of
pNFkB-mediated luciferase activity in reporter construct transfec-
tion experiments with the colon tumour cell line SW480. These
results indicate that the colon cancer chemopreventive effects of
CUR may be mediated in part through down-regulation of COX2
gene expression through inhibition of NFkB activation.
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Cancer in the parents of children with
medulloblastoma
V Blair, JM Birch, AM Kelsey and M Newbould
CRC Paediatric & Familial Cancer Research Group, Royal Manchester
Children's Hospital, Manchester M27 4HA, UK
Medulloblastoma occurs in families with genetic syndromes, such
as Li-Fraumeni (LFS) and Gorlin's syndrome (GS). To estimate
cancer risks in parents of children diagnosed with medulloblas-
toma before age 15 years and the proportion of paediatric medul-
loblastoma cases that might have a genetic component, 167 cases
diagnosed from 1954 to 1993 and registered with the Manchester
Children's Tumour Registry were identified. A total of320 parents
were traced and flagged. Numbers of cancers expected in the
parents in the period from the latest of 1 January 1965 and the birth
ofthe case to the earliest of31 December 1993; date oflast follow-
up and 75th birthday were calculated from population rates for the
NW of England and compared with observed numbers, which
were assumed to follow a Poisson distribution. Two-sided hypoth-
esis tests were performed to determine whether observed numbers
differed significantly from those expected. Overall, 21 cancers
were observed and 21.86 expected (RR = 0.96, 95% CI 0.59-1.47,
P = 0.97). Eight breast cancers occurred in mothers, but only 3.33
were expected (RR = 2.4, 95% CI 1.04-4.73, P = 0.04). The
excess of breast cancers was significant for mothers of cases diag-
nosed under the median age (7 years) at onset (0 = 6, E = 1.75,
RR = 3.43, 95% CI 1.26-7.46, P = 0.02) and of women (0 = 4,
E = 1.09, RR = 3.65, 95% CI 1.00-9.36, P = 0.05), but not for
mothers of cases diagnosed aged 7 and above (0 = 2, E = 1.57,
RR = 1.27, 95% CI 0.15-4.59, P = 0.93) or of men (0 = 4, E =
2.23, RR = 1.79, 95% CI 0.49-4.59, P = 0.37). No other cancers
occurred to excess but, overall, a significant deficit occurred in
fathers that could not be accounted for by underascertainments
(0 = 3, E = 11.6, RR = 0.26, 95% Cl 0.05-0.76, P = 0.006).
Twenty-three families in which a parent was diagnosed with
cancer were interviewed or completed a questionnaire. Inspection
of the pedigrees identified the following families: one LFS, one
Li-Fraumeni-like, two GS, one FAP and five with potentially
interesting clusters of cancers. The percentage ofmedulloblastoma
cases identified by this method to be associated with a genetic
component was 3-6%.
Seasonal variations in the onset of
childhood leukaemia and lymphoma
RMC Westerbeek, OB Eden, V Blair, AM Kelsey and
JM Birch
CRC Paediatric & Familial Cancer Research Group, Royal Manchester
Children's Hospital, Manchester M27 4HA, UK
Infection is suspected to be a factor in the aetiology of leukaemia.
If seasonal variation in onset of leukaemia or lymphoma could be
demonstrated, this would provide support for a link with exposure
to infection. Therefore, all cases in the Manchester Children's
Tumour Registry diagnosed with acute lymphoblastic leukaemia
(ALL), acute non-lymphocytic leukaemia (ANLL), Hodgkin's
disease (HD) or non-Hodgkin lymphoma (NHL) between I
January 1954 and 31 December 1996 were included in an analysis
of seasonal variation in the month of first symptom and the month
of diagnosis. Cases of common ALL (c-ALL) diagnosed from
1979 onwards were also analysed separately. The groups consid-
ered for analysis were all cases ofALL (n = 1070), ALL diagnosed
under 18 months of age (n = 74), ALL diagnosed between 18 and
95 months (n = 730), ALL diagnosed over 95 months (n = 266), c-
ALL (n = 309), ANLL (ni = 244) HD (n = 166) and NHL (ni = 189).
Data analysis included chi-squared test for heterogeneity to look
for departure from a uniform distribution throughout the year and
Edward's test to detect cyclical trends (sinusoidal curve of period
12 months) over the year. Tests for heterogeneity based on date of
first symptom were significant for HD (P = 0.002) and of border-
line significance for ALL aged 0-179 months (P = 0.055) and c-
ALL (P = 0.056). Tests for cyclical trends based on date of first
symptom were significant for c-ALL (P = 0.037), with peak month
November, and HD (P = 0.001), with peak month December, and
ofborderline significance for ALL aged 0-179 months (P = 0.07),
with peak month March. No evidence of seasonal variation was
found in other diagnostic groups for date of first symptom or in
any diagnostic group for date of diagnosis. These results provide
supportive evidence for an infectious aetiology in c-ALL and HD.
Date of first symptom may reflect actual biological onset more
accurately than date of diagnosis.
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